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Abstract
Magnetic resonance imaging (MRI) has become a powerful clinical modality in
diagnostic medicine. It is non-invasive and offers high spatial and temporal resolution.
The goal of molecular imaging is to reveal the pathophysiology underlying the observed
anatomy and diagnose diseases. The detection of pathological biomarkers can lead to
early recognition of diseases and improved monitoring for recurrence.

Clinically

available contrast agents are limited in their discrimination of contrast between tissues
and they tend to have very high detection limits. Because biomarkers are very low in
concentration there is a need for high payload deposition of contrast agent (CA) and
targeted imaging.

Encapsulating discrete Gd3+ chelates in nano assembled capsules

(NACs) is a simple and effective method of preparing an MRI contrast agent capable of
delivering a large payload of high relaxivity imaging agent. The preparation of contrast
agent containing NACs had previously focused on preparations incorporating GdDOTP5into the internal aggregate. In this report we demonstrate that other Gd3+ chelates bearing
overall charges as low as 2- can also be used to prepare NACs. This discovery opens up
the possibility of using Gd3+ chelates that have inner-sphere water molecules that could
further increase the relaxivity enhancement associated with the long rotational correlation
time (R) that arises from encapsulation. However, encapsulation of the q = 1 chelate
GdDTPA2- afforded the same increase in relaxivity as the outer-sphere chelate
GdTTHA3-. This leads us to the conclusion that in the NAC interior proton transport is
not mediated by movement of whole water molecules and the enhanced relaxivity of
Gd3+ chelate encapsulated within NACs arises primarily from second sphere effects. The
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nano assembled capsule platform has been further expanded by an alternative coating
method, a new cross linked peptidic shell reported in this work affords robust capsules
and exceptionally high per Gd3+ relaxivities (70.7 mM-1s-1). The availability of free
amines on the surface of these capsules can be exploited to attach targeting moieties.
This was demonstrated through the reaction of fluorescein isothiocyanate (FITC), an
intense green emitting dye, with these amines.

Green emission from the capsules

indicated that surface amines were accessible to FITC. Unlike T1-shortening contrast
agents, paraCEST agents can be switched on and off by the imaging scientist by turning
on and off a pre-saturation pulse. This affords the ability to acquire both pre- and postcontrast images even after administration of a paraCEST contrast agent. This could
potentially eliminate problems co-registering pre- and post-contrast images. A reverse
NAC may allow a cationic paraCEST contrast agent to be incorporated in a high payload
NAC. We were successful in synthesizing a reverse capsule using DyDOTAM3+, a
paraCEST agent, and the negatively charged polymer polyacrylate and encapsulated with
SiO2 nanoparticles. These initial preparations of reverse NACs were not able to generate
CEST contrast however.
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Chapter 1: Introduction
1.1 A look back at where we have been and where we are
Medical imaging has revolutionized medicine, since the discovery of X-rays in 1895 by
Roentgen1.

Various imaging modalities have been developed which include

computerized tomography (CT), optical imaging; ultra sound and nuclear imaging (such
as PET and SPECT) are some of the well-known rapidly growing and frequently used
medical diagnostic tools.2

X-ray imaging utilizes high frequency characteristics of

electro-magnetic rays which when passed through human body they are absorbed in
different amounts depending on the density of the tissue. Even though the X-rays are
quick and non-invasive the ionizing radiation has several side effects3, high dose of Xrays can damage DNA in cells and increases the risk of getting cancer by about 0.08%.
In the mid-1970s CT came into use; it is an X-ray based technique developed by Godfrey
Hounsfield. It is a combination of a computer and X-ray technologies, used to provide
cross sectional images of the body. It was Lazaro Spallanzani who started the study
related to ultra sound in 1794 and Karl Dussik in 1942 introduced ultrasound into the
field of diagnostics. It is a medical imaging technique that uses high frequency sound
waves and their echoes. It has an advantage of low cost4 and is noninvasive also it does
not require ionizing radiation5-7, versatile8 and portable9-13. Ultra sound is mainly used as
part of routine checkup in case of pregnancy to check fetus in womb. In the 1950s
nuclear imaging techniques entered the field of diagnostic imaging test. Nuclear imaging
methods employ radioactive tracers which ultimately cause the emission of gamma rays.
Nuclear imaging is a combined study of physics, chemistry, mathematics, computer
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science and medicine. Nuclear imaging commonly used in detecting various infections
and injuries4. It is considered a non-invasive technique5. Positron Emission Tomography
(PET) and Single Photon Emission Computed Tomography (SPECT) are types of nuclear
imaging. In PET the tracer emits a positron when it decays, when the positron collides
with an electron they mutually annihilate and two gamma rays are simultaneously
emitted.14,

15

In SPECT radioactive tracer itself emits a gamma ray. In both cases

detection of the gamma rays allows an image to be built up.16, 17 The major disadvantage
of nuclear medicine is the use of radioactive tracers and cost.
In the 1970s Magnetic Resonance Imaging also evolved. At first resistive magnets with
weak magnetic fields were used, producing images with low spatial resolution. Despite
this it still had a better soft tissue discrimination than CT allowing earlier diagnosis18. In
the late 1980s the super conducting magnets became popular 1.5 Tesla. MRI has the
added advantage over X-Ray based CT for not requiring ionizing radiation and MRI has a
high spatial resolution compared to the other techniques15, 19, it can be used to evaluate
heart, kidneys, liver, blood vessels20 and other body tissues17.

All the diagnostic

techniques have now grown from a state of infancy to a high level of maturity. 21

1.1.1. A history of MRI
Since William Roentgen first discovered the X-ray phenomenon in 189522 medical
imaging techniques have become irreplaceable tools in the diagnosis and treatment
supervision. Before the development of the imaging modalities the ability to see inside
the human body historically was to have surgery. One key advance in the development
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of modern imaging techniques came in 1822 when the French mathematician and
physicist Joseph Fourier proposed that a function could be represented by a series of
sinusoids. The resulting mathematical transformation, later named Fourier transform,
forms the basis of Magnetic Resonance Imaging. A further concrete step towards MRI
was the Austrian physicist Wolfgancy Pauli’s prediction of the existence of nuclear spin,
in 1924. The concept of nuclear spin is central to the development of nuclear magnetic
resonance methods. At Columbia University a group led by Isidor Isaac Rabi showed
that an oscillating magnetic field could be used to induce transitions between nuclear spin
states of lithium and chlorine atoms in a molecular beam eventually leading to the award
of a Nobel Prize in physics in 1944. The extension of Rabi’s 1938 observation of NMR
in a beam of independent molecules to solid and liquid samples was successfully
independently and simultaneously in 1948 Felix Bloch23 and Edward Purcell observed
that signal is emitted from a sample in a magnetic field when it is irradiated with an
electromagnetic energy of a particular frequency. They shared the Nobel Prize in physics
in 1952 for this discovery of condensed phase magnetic resonance. Although Rabi’s
work was crucial as the conceptual and technical leap achieved by Bloch and Purcell
really set the stage for the development of modern NMR and MRI. Independently Henry
C Torrey and Erwin L Hahn contributed a final critical component of the modern NMR,
they demonstrated the feasibility of pulsed NMR, an idea originally suggested by Bloch
and observed free Larmor precession.

Independently Paul Lauterbur, Raymond

Damadian and Peter Mansfield introduced methods to allow images of the human body to
be acquired, including slice selection and fast acquisition. Research in MRI was largely
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restricted to academic laboratories during the 1970s. William Edelstein a post-doctoral
fellow in Mallard’s group implemented Fourier imaging and obtained the first clinically
useful image of a human subject. All demonstrated the imaging potential of NMR and
MRI was finally born. In 2003 Lauterbur and Mansfield were awarded Nobel Prize in
medicine for their development of magnetic resonance imaging. As a non-invasive
imaging tool Magnetic Resonance Imaging (MRI) is less harmful than other imaging
modalities that use ionizing radiation or radioactive tracers, such as X-Rays and PET.

1.2 Basic principle of Magnetic Resonance
Magnetic resonance imaging is one of the most widely used techniques in diagnosis,
clinical medicine and biomedical research.

The basis of MRI is nuclear magnetic

resonance. 1H is the most favorable nucleus for MRI because of its abundance in biology
(water), and its high gyromagnetic ratio. When a human body is placed in a large
magnetic field the magnetic moments of the proton nuclear spins tend to align slightly
either with or against the magnetic field (Figure 1.1). There is a slight predominance of
nuclei in the lower energy state (slightly more aligned closely with the magnetic field),
than there are in the high energy state (slightly more aligned against the field). This
produces a small net magnetic moment, the magnitude of which can be described by the
Boltzmann equation (Eqn 1), which can be probed with radiofrequency radiation.

𝑁− 1⁄

2

𝑁+ 1⁄

=𝑒

−∆𝐸⁄
𝑘𝑇

2

Equation 1: Boltzmann distribution
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Where ∆E is the energy difference between the two levels and k is the Boltzmann
constant and T is the temperature in Kelvin.

Figure 1.1: Illustration to represent spins in the absence (left) and presence (right) of a
strong external magnetic field
The magnetic dipole moment of a nucleus is directly proportional to the spin angular
momentum, nuclear spin angular momentum is a fundamental property that makes a
nucleus a continuously rotating positive charge, and as a moving charge it has an
associated magnetic field and magnetic dipole moment and the magnetic dipole moment
is directly proportional to the spin angular momentum. It is the gyromagnetic ratio that
relates the nuclear rotating frequency to the strength of the magnetic field. For hydrogen
the gyromagnetic ratio is 42.6 MHz / T. Nuclei of hydrogen contain a single proton
giving them a net nuclear spin of ½. Its high gyromagnetic ratio and its high biological
and isotopic abundance make the proton ideal for MRI. In the absence of a strong
external magnetic field individual nuclear magnetic moments are randomly distributed
and precess incoherently. However, in a strong external magnetic field a radio frequency
pulse can be used to apply torque to the net magnetic moment causing coherent
precession. The frequency at which the spins precess is called the Larmor frequency ()

CHAPTER 1. Introduction

6

and is given by the product of the gyromagnetic ratio () and the strength of the applied
magnetic field (B) (Eqn 2). Gyrometric ratio relates nuclear rotating frequency to the
strength of the magnetic field and is expressed in terms of MHz per tesla in MRI
𝜔 = 𝛾𝐵
Equation 2: Larmor frequency
Even though individual spins obey the laws of quantum mechanics, the behavior of a
group of spins experiencing the same magnetic field strength is best described using
classical mechanics. Therefore the vector sum of the magnetization vectors from all spin
packets is represented by a net magnetization M0.

Figure1.2: In the presence of static magnetic field, the spin magnetic moments and the
resulting bulk magnetization precess at the Lamor frequency around the magnetic field
At equilibrium the net magnetization vector aligns with the main magnetic field along the
z-axis. On applying a radio frequency pulse B1, at or near the Larmor frequency of the
protons. The magnetization vector is “tipped” such that component lies in the transverse
(x-y) plane. Precession of the net magnetization vector around the z-axis at the Larmor
frequency induces a current in the receiver coil, which after amplification and processing
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afford the NMR signal. This process is independent of the return to equilibrium also
known as relaxation.
1.2.1: Inversion recovery pulse sequence
Inversion recovery pulse sequence is used to measure T1. It begins with a 180° inverting
pulse which flips the initial longitudinal magnetization (M0) to point antiparallel the main
magnetic field B0. After switching the 180º radio frequency off, the net magnetization
begins to recover to its equilibrium position. At a time interval (t) after the 180º pulse a
90º interrogation pulse is acquired, this rotates the longitudinal magnetization into the x-y
plane. This allows the extent of recovery of the longitudinal relaxation to be read out;
repeating this exercise while varying the value of the time interval t allows a recovery
curve to be generated from which the longitudinal relaxation time constant, T1, can be
determined.24

Figure1.3: Representation of the inversion recovery process. The magnetization vector
M0 in the equilibrium state. B) Inversion of M0 after 180o pulse. C) Spins precessing in xy plane. D) Recovery of the magnetization factor along the z-axis
1.2.2 Relaxation
After the radiofrequency pulse is turned off the excited nuclear spins begin to return to
their original stable equilibrium state. This process is facilitated by modulating local
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magnetic fields. The net magnetization vector M0 gradually returns to lie along the z-axis
(longitudinal relaxation). Concurrently there is dephasing (loss of coherence) of the net
magnetization vector (transverse relaxation). These two processes are two types of
relaxation in NMR sometimes called spin-lattice (longitudinal relaxation) and spin-spin
(transverse relaxation).
1.2.3: Spin-Lattice relaxation, T1
Spin lattice relaxation, also called longitudinal relaxation is the recovery of net
magnetization towards z-axis and involves an exchange of energy between spin systems
and surrounding or lattice.
Rotational and vibrational motion modulates local magnetic fields in the lattice and some
components of this magnetic field have a frequency equal to the Lamor frequency and
can therefore facilitate nuclear relaxation. Relaxation arises from this dipole-dipole
interactions. Energy rate loss indicates how closely spins are coupled to the lattice.
Hydrogen in the form of water is a small molecule so it moves more rapidly, while large
molecules like fat molecules move much more slowly. T1 relaxation time shows the
relationship between the frequency of these molecules and the Lamor frequency. If these
frequencies are the same, T1 recovery of Mo is rapid and if they are different the T1
recovery is slow as a result different tissues exhibit different T1 recovery curves. Spinlattice relaxation is described by an exponential function characterized by a time constant
T1, the period for the longitudinal magnetization to recover 63% of its equillibrium value.
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Figure1.4: Principle of magnetic resonance imaging (MRI). A) Spins in the presence of
external magnetic field. B) Spins precessing in x-y plane at the Larmor frequency upon
applying a radiofrequency C) Spins decaying to their original z-axis. D) Spins back to
their original z-axis
1.2.4: Spin- Spin relaxation, T2
Transverse relaxation is also called spin-spin relaxation. After a 90° pulse is applied the
net magnetization vector is in the transverse plane. When the radio frequency pulse is
switched off each individual spins that makes up the net magnetization vector lie in
transverse plane but they do not all experience exactly the same local magnetic field.
This means that they will precess at slightly different rates and the population of spins
begins to dephase or lose phase coherence. This loss of coherence means that the
magnitude of the net magnetization vector decreases leading to a loss of signal. This
process is also dependent on the rate of molecular motion and so its rate also varies
between tissues.

Larger macromolecules like in fat experience more static internal
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magnetic fields and consequently more rapid transverse relaxation. Spin-spin relaxation
is described by an exponential decay function characterized by the time constant T2, as
shown in Figure 1.5.

Figure1.5: Spin-spin relaxation describes the transverse component decay as a function
of time and is characterized by T2

1.2.5: Relaxivity
The efficacy of a contrast agent on relaxation is often expressed in terms of relaxivity
either r1 or r2 to describe the effect on longitudinal and transverse relaxation,
respectively. Relaxivity is defined as the relaxation rate constant (either 1/T1 or 1/T2) per
millimolar concentration of the contrast agent.
1.3: MRI Pulse sequences
An MRI pulse sequence is a set of RF pulses applied to a sample to produce a specific
form of MRI signal. It is programmed with a set of changing magnetic gradients and
each sequence has a set of parameters which are described in an MRI protocol.
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Repetition time (TR) and Echo time (TE) are parameters that are varied to highlight or
suppress different tissues, reduce imaging times and reduce or avoid artifacts. There are
two major sequences in MRI: the spin echo and the gradient echo.
1.3.1: Spin echo sequence
In a spin echo sequence, the spins are excited by a 90º pulse. After a short time a 180°
radio frequency pulse is applied which reverses the phase of precession causing the
dephasing magnetization vector to rephrase. This creates an echo which occurs at the
echo time TE (TE = 2 × the time between the 90º and 180º pulses). This helps to reduce
the effects of magnetic field inhomogeneities. The magnitude of the echo depends on
value of T2* which reflects magnetic field homogeneity. Gradient echo pulse sequences
differ from the spin echo in that they can use field gradients, rather than a radiofrequency
pulse, to generate the echo.

Figure1.6: Illustration of pulse sequence diagram for inversion recovery pulse sequence.
A 180° pulse sequence inversion is applied followed by a 90° recovery pulse, as well as a
180° repolarization pulse
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1.3.2: Repetition Time (TR)
The Repetition Time, TR, determines how much longitudinal magnetization recovers
between each radio frequency pulse. It is the time from the application of an excitation
pulse to the application of the next pulse. If the repetition time is shorter than the time it
takes to fully recover longitudinal magnetization returns to its equilibrium position then
the signal will be attenuated.

The extent of attenuation will depend upon the T1

relaxation time constant.
1.3.3: Echo Time (TE)
The Echo time is time between the application of radio frequency excitation pulse and the
peak of the echo signal induced by the 180º pulse (Figure 1.6). An underlying limitation
of MRI is that measurement of signal is not possible immediately after the application of
the excitation pulse therefore the signal must be preserved by a refocusing (echo) pulse.
The magnitude of the echo signal is dependent on the echo time. The longer the echo
time the more magnetization is lost unrecoverable to dephasing and the lower the signal.
Varying the repetition and echo times are the primary means by which image contrast is
manipulated. In spin echo sequences there are three main parameters that affect the
weighting of an image: T1, T2 and proton density.
1.3.4: T1 weighted images
Image contrast can be adjusted by varying the repetition time and echo time values. The
selection of a short TR will prevent complete recovery of magnetization in tissues with
shorter T1 relaxation time constants.

A short TE ensures that the maximum
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magnetization is retained in the transverse plane and the effect of T2 is minimized. This
is known as T1.-weighting – it results in image contrast that is more dependent on
differences in T1 than differences in T2. The effect of T1 weighting on an MRI of the
brain can be seen in Figure1.8. it can be seen for example that fat has a shorter T1
(because it has a relatively slow tumbling rate which is similar to that of the Larmor
frequency) and thus appears with stronger signal intensity while water, which has a
relatively longer T1 (due to relatively high tumbling rate which does not match the
Larmor frequency), appears with lower signal intensity on T1 weighted MR images.

Figure1.7:T1 contrast difference between water and fat
1.3.5: T2 weighted images
If TR is made long then the effect of T1 on image contrast is minimized. The image can
be made to reflect differences in T2 between tissues if a longer echo time is selected.
Longer T2 values mean that more coherent magnetization remains in the transverse plane
when the echo pulse is applied and this leads to a stronger signal. A shorter T2 value (e.g.
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10 - 20 ms)25 causes more loss of coherence and therefore a weaker echo signal. Images
acquired with long TR and TE values reflect differences in tissue T2 and are therefore
known as T2-weighted images. When selecting a long repetition time and a short echo
time, the dependence of image contrast on T1 and T2 becomes insubstantial and contrast is
instead determined by proton density of the tissues.

Figure1.8 : Axial brain MRI image of the same tissue showing how image weighting can
be used to vary the contrast between grey matter, white matter and cerebrospinal fluid a)
T1 weighted b) proton density and T2 weighted MRI images26

Figure1.9 :T2 contrast between fat and water
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1.3.6: Proton density weighted images
Besides the differences in relaxation times in different tissues, differences in the proton
density per unit volume can also contribute to contrast in MR images. Proton density
images are collected such that the effects of relaxation are minimized: i.e. TE ≪ T2 and
TR ≫ T1.

Under these circumstances contrast will therefore mainly reflect proton

density. Tissues with a high proton concentration will appear bright like brain tissues
whilst tissues with low hydrogen content will appear dark e.g. cortical bone.
Table 1: Contrast in spin echo images is determined by the choice of TR and TE times
Spin Echo imaging

Short T2

Long T2

Short TR

T1 weighted

-

Long TR

Proton density

T2 weighted

1.4: Imaging with Contrast agents
Sometimes the inherent contrast in MRI is insufficient for the proper characterization of
the anatomy or pathology of interest, even after applying appropriate pulse sequences. In
these cases, a contrast agent can help amplify the differences between healthy and
pathological regions.

The major reason of using contrast agents is to increase the

relaxation rate constant of water protons in the tissue to which it is distributed. This is
achieved by use of a paramagnetic element. Bloch and co-workers reported use of ferric
nitrate to enhance the relaxation rate constants of water protons and 30 years later
Lauterbur and co-workers used Mn2+ salts to differentiate water phantoms based on their
relaxation rate constants. The fluctuating magnetic field around the paramagnetic center
of the contrast agent administered due to unpaired electrons is responsible for increasing
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the relaxation rate constant of nearby water protons. The relaxivity of a contrast agent is
a measure of its ability to increase the relaxation rate constant of water. The relaxivity of
a contrast agent is described by a model that considers three contributions: the inner
coordination sphere (which is defined by the exchange of water directly coordinated to
the metal center); the outer hydration contribution (consisting of water molecules that are
not directly coordinated to the metal center but are diffusing close to the metal ion); and
the second hydration sphere (defined by exchange of protons that are weakly associated
with the chelate but not bound to the metal ion).27 The overall relaxivity is made up from
contributions from each of these solvation spheres according to Eqn 3.
𝑟1𝑜𝑏𝑠 = 𝑟1𝐼𝑆 + 𝑟1𝑆𝑆 + 𝑟1𝑂𝑆
Equation 3: Contribution of hydration spheres to overall observed relaxivity
1.4.1: Inner sphere relaxivity
The relaxation arising from exchange of inner sphere water molecules can be described
by the Solomon- Bloembergen-Morgan (Eqns 4, 5, and 6). When one or more water
molecules are coordinated to a paramagnetic metal ion the largest contribution to the
overall relaxivity comes from these molecules exchanging with the bulk water according
to Eqn 4. Currently, all clinically available contrast agents are gadolinium based chelated
with organic chelators polyaminocarboxylates with one exchanging water molecule.

𝒓𝑰𝑺
𝟏𝒑 =

[𝑪]𝒒
𝟏
(
)
𝟓𝟓. 𝟔 𝑻𝟏𝑴 + 𝝉𝑴

Equation 4: Inner hydration sphere relaxivity
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q is the number of water molecules which are coordinated to the central metal ion
(hydration number), C is the molar Gd3+ ion concentration, T1M is the relaxation time
constant of the bound water protons and 𝜏𝑀 is the mean residence time of the protons
bound to the water molecules in the inner coordination sphere. The value T1M, can be
obtained by using Solomon-Bloembergen-Morgan (SBM) theory (Eqns 5 and 6)27.

𝟏
𝟐 𝜸𝟐𝑯 𝙜𝟐 𝑺(𝑺 + 𝟏)𝜷𝟐
𝟑𝝉𝒄𝟏
𝟕𝝉𝒄𝟐
=
[
+
]
𝑻𝟏𝑴
𝟏𝟓
𝒓𝑮𝒅𝑯 𝟔
𝟏 + 𝝎𝟐𝑯 𝝉𝟐𝒄𝟏
𝟏 + 𝝎𝟐𝒔 𝝉𝟐𝑪𝟐
Equation 5: Solomon-Bloembergen theory

1
𝜏𝐶𝑖

=

1
1
1
+
+
𝜏𝑅
𝜏𝑀
𝑇1𝑒

𝑖 = 1,2

Equation 6: Solomon-Bloembergen-Morgan equations

CHAPTER 1. Introduction

18

S is the electron spin quantum number, 𝛾 is the proton nuclear magnetogyric ratio,
where ωH and ωs are the proton and electron larmor frequency respectively, 𝛽 and g are
the electronic factor and Bohr magneton, respectively. 𝑟𝐺𝑑𝐻 is the distance between the
metal ion and the protons of the coordinated water molecules, 𝜏𝑐𝑖 (i = 1, 2) are the
correlation times of the modulation of dipolar electron-proton coupling, the correlation
time 𝜏𝑐𝑖 of paramagnetic metal complex reflects weighted contributions from, R, the
rotational correlation time of the Gd3+ chelate, Tie the electronic relaxation time of the
Gd3+ ion and 𝜏𝑀 the mean residence life time.

1.4.2: Second hydration sphere relaxivity
Water molecules not directly coordinated to the metal centre may also contribute to a
relaxation enhancement from the contrast agent. The second hydration sphere consists of
water molecules that are weakly asscoiated with the contrast agent.

For example

hydrogen bonding interactions with the ligand tend to increase the residence time close to
the paramagnetic ion. SBM theory also describes the contributiom of second sphere
relaxivity and the same parameters govern second sphere relaxivity as inner sphere
relaxivity. However, unlike the inner sphere water, the number of the second sphere
water molecules be quite large without decreasing the densicitity of the chelating ligand,
reducing the chelate’s thermodynamic stability. The life time of hydrogen bonded water
molecules in the second sphere can be very short, groups that can increase this life time
will promote second sphere relaxivity.
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Figure1.10 : Schematic diagram showing the three hydration spheres, inner sphere
water molecules are directly bound to the metal center; second sphere consists of water
molecules coordinated to the ligand of the CA and the outer sphere water molecules
1.4.3: Outer sphere relaxivity
The contribution of the outer sphere has been shown to be approximately 1.8 mM-1s-1(20
MHz, 25℃) of total relaxivity5. The main determinants of outer sphere relaxivity are the
relative diffusion coefficient of the dissolved substance and solution (D), the distance of
closest approach (a) and the electronic relaxation rate constants of the paramagnetic ion.
The mechanism of outer sphere relaxivity is essentially the same those of the second and
inner spheres: modulation of dipole-dipole interactions between the electronic spin and
the proton spin, however in this case the distance are greater and timing is governed by
the rate of diffusion of the water molecules in close proximity to the paramagnetic centre.
The diffusion of the paramagnetic chelate in solution is usually described by the Freed
equations.28, 29 The general form of theory of outersphere relaxivity has similarities with
the SBM equations as shown in Eqn 7.
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1
𝑇1(𝑜𝑠)

𝐶𝜋 𝑁𝑠 𝛾𝐻2 𝛾𝑆2 ℏ2 𝑆(𝑆 + 1)
=
𝑑 3 𝜏𝐷

Equation 7: Outer sphere relaxivity Solomon-Bloembergen equations
Here C is a numerical constant, 𝑁𝑠 is the number of metal ions per cubic centimeter, D is
the relative translational diffusion time, and 𝛾𝐻 and 𝛾𝑠 are diffusion constants of water
proton and the metal complex, respectively. Furthermore, if molecular motion, described
by the Stokes–Einstein model, is considered then diffusion can be approximated as the
diffusion of rigid spheres in a medium of viscosity () (Eqn 8).

D =

𝑘𝑇
6𝜋𝑎𝜂

Equation 8: Einstein model for diffusion for rigid spheres
For small paramagnetic metal chelates the Freeds equation can be modified as in Eqn 9.

𝑅𝑜𝑠 =

𝑐 𝑜𝑠 (

1
)[7J(𝜔𝑠 ) + 3J(𝜔𝐻 )]
𝑎𝐷

Equation 9: Freeds equation modification
For q = 1 systems like GdDOTA1- and GdDTPA2- the overall contribution from the outer
hydration sphere is 40–50 %30.

Contribution from outer sphere hydration is more

pronounced in chelates like GdTETA1- and GdTTHA3- (q = 0 chelates), which have no
inner sphere contribution and relatively small second sphere contributions. In the case of
a q = 0 chelate such as GdDOTP5- the outer sphere contibution is close to half of the
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overall relaxivity, with the remainder arising from a large second sphere contribution
facilitated by the phosphonates groups coordinated to the paramagnetic centre.
1.4.4: Contrast agents
Contrast agents are not directly detected but their effect on the surrounding water
molecules, in the form of increases to the rate of relaxation that are detected. Contrast
agents change the intensity of the water proton signal in appropriately weighted images.
Gd3+ is the most frequently used paramagnetic ion due to its particularly favorable
characteristics; the high spin state (seven unpaired electrons) of the 3+ oxidation state and
the long electronic relaxation time constants, which are much longer (approximately 10-9
s) than for the other lanthanides such as Dy3+, Ho3+ and Eu3+.31 Unfortunately, free Gd3+
ion is toxic in vivo. The use of Gd3+ in chelate becomes form is therefore mandatory in
biomedical applications to reduce toxicity and increase solubility of free lanthanide aqua
ions at physiological pH. The toxicity of Gd3+ arises due to the comparable ionic radii of
Gd3+ to Ca2+ which causes the lanthanide to interfere with the Ca2+ signaling channels.32
Chelation reduces relaxivity since it decreases the number of coordination sites available
for water proton exchange, from 8-9 sites for aquated Gd3+ ions compared to 1-2 sites for
Gd3+ chelates.

Clinically available contrast agents (Figure 1.11) tend to have

comparitively low relaxivity, approximately 4 mM-1s-1 (20 MHz, 25 ºC). This is much
lower than the theoretically predicted maximum,33 assuming that all the parameters that
affect relaxivity are optimized. The Gd3+ chelates used in clinical MRI are derived from
linear

and

macrocyclic

polyaminocarboxylates

such

as

DTPA(diethylenetriaminepentaacetic acid), DOTA (1,4,7,10-tetraazacyclododecane-
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1,4,7,10-tetra acetate).34 These chelates have extremely high thermodynamic stability
constants log 𝐾𝐺𝑑𝐿 = 23.6 and 25.3 for GdDTPA2- and GdDOTA1-, respectively, in
addition to retaining one vacant coordination site for an inner sphere water molecule.

Figure1.11 : Contrast agents approved for clinical use, with common name and brand
They have extremely high Gd3+thermodynamic formation constants log 𝐾𝐺𝑑𝐿 = 23.6 and
25.3 respectively and a coordination site for an inner sphere water molecule.
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1.4.5: Parameters that affect relaxivity
The theory of T1 contrast agents clearly shows that numerous parameters affect relaxivity
as shown in scheme 1. The hydration number (q), the rotational correlation time (R) and
the water residence life time (M) can all be adjusted by altering the chemical
environment around the paramagnetic ion.

Altering these parameters can have a

significant effect on the overal relaxivity value of the chelates.

Scheme 1: Schematic presentation of the factors that affect relaxivity with one innersphere water molecule, R refers to the rotational correlation time of the molecule, m
mean water residence life time and T1, T2e relaxation times of the Gd3+ electron spin
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1.4.6: The hydration number (q)
The hydration number (q) is the number of water molecules that can directly coordinate
to the paramagnetic metal ion. The inner sphere relaxation increases linearly with an
increasing q. Current clinical contrast agents utilize polyamino-carboxylate chelating
ligands that bind Gd3+ with a coordination number of eight, leaving one available
coordination site for the binding of water. The reason for this is the necessity to balance
both stability and relaxivity while designing contrast agents. Although there are new
chelates being tested which have more than one water molecule coordinated to the metal
centre.35 There is always an underlying concern over the use of contrast media with
hydration numbers greater than 1. Surprisingly, despite possessing no inner sphere water,
chelates like GdDOTP5- have higher relaxivity than q = 1 chelates like GdDOTA-. The
phosphonates groups on GdDOTP5- can interact with an estimated 6 water molecules in
the second sphere and keep them bound for longer (~ 50 ps) than second sphere waters in
carboxylate chelates. For these reasons the contribution of outer sphere hydration more
than compensates for the absence of an inner hydration sphere.36
Efforts have been undertaken to increase the number of water molecules directly
coordinated to the metal centre. GdDOTA has been modified to increase q = 1 to q = 2
by removal of an acetate group creating a seven coordinate complex GdDO3A. The
relaxivity of GdDO3A is r1 = 4.8 mM-1s-1 (20 MHz, 40℃), under the same conditions
GdDOTA1- has a relaxivity of 3.5 mM-1s-1.37 The overall difference of relaxivity is
attributed to an increase in hydration number. However, this increase in relaxivity comes
at the cost of a deacrease in the thermodynamic stability constant by three orders of
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magnitude.38, 39 Ken Raymond and co-workers have devoloped recently a ligand with a
hydration number of two and rather than traditional poly(amino-carboxylate) complexes
these ligands are comprised of all oxygen donors and are based on hydroxy pyridinone
(HOPO) ligands. Gd-TREN-1-Me-3-2-HOPO is the first such ligand that provides two
positions for water coordination without compromising thermodynamic stability40.
1.4.7: Water residence lifetime (𝜏M)
Water proton exchange is a key factor in governing relaxivity because the relaxation
effect is transferred to the bulk water protons through water exchange between the
paramagnetic center and the surrounding bulk water. However, relaxivity can be limited
due to water exchange that is either too fast or too slow. Fast water exchange results in a
very small water residence life time 𝜏𝑀 of the water molecule coordinated to the
paramagnetic center which is usually not long enough to allow water to be properly
relaxed. Water exchange that is too slow will also result in poor relaxivity due to poor
transmission of the relaxation effect from the paramagnetic center to the bulk water. An
optimal value of 𝜏𝑀 is dependent on magnetic field strength and 𝜏𝑅 of the complex.
In lanthanide chelates, water can be in exchange occur through an associative or
dissociative mechanism. In Gd3+ aqua ion is an eight/nine coordinate system which
exchanges through an associative pathway. However, in nine-coordinate mono-hydrated
exchange can occur only through a dissociative mechanism since there is no availlable
site for a second water to bind. Complex charge, solvent accessibility, steric effects
around the water binding site of chelates are all key factors that govern M. Negatively
charged Gd3+ complexes of DOTA or DTPA-like ligands demonstrate shorter residence
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life time than neutral or positively charged chelates. M should be short, in the range of
10 −30 ns, for macromolecular contrast agents at 60 MHz or 1.5 T. For higher fields a
𝜏𝑀 in the range of 3-10 ns is predicted to be optimal41. The polyaminocarboxylate
chelates used as clinical contrast agents exchange more slowly than this. Merbach and
coworkers increased steric crowding of mono aqua GdDTPA2- and GdDOTA1- chelates
by substituting one or two of the ethylene bridges with propylene bridges42. Despite
having a small effect on the stability of the chelate this induced steric effect on the Gd3+
center facilitates the leaving of the bound water, resulting in an increase in water
exchange rate from about 30-50 fold for GdDOTA1- analogues and 40 -50 fold for
GdDTPA analogues. Square antiprismatic (SAP) or twisted square antiprismatic (TSAP)
isomers observed in Ln (DOTA) complexes and their derivatives have different values.
Reports display 10–100 times faster water exchange for TSAP isomer when compared to
SAP.43-46
1.4.8: Rotational correlation time (R)
Molecular tumbling usually relates to molecular size. The relaxvity of a Gd3+ chelate
increases with increasing R. The minimum value of R that will afford an increase in
relaxivity depends on the magnetic field and occurs most efficiently between the Lamour
frequencies of 10−70 MHz and when M is between 10−50 ns. A number of strategies
have been used to reduce the tumbling rates of contrast agents by covalent or noncovalent attachment to macromolecules.47 dendrimers, liposomes48,
micelles50 and solid nanoparticles.51,52,

49

carbohydrates,

Self-assembled Fe[Gd2bpy(DTTA)2(H2O)4]53

agents displayed four times higher in vivo relaxivity than the commercially available
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GdDOTA1-. When the clinical agent MS-325 binds to human serum albumin (HSA)
using a hydrophobic diphenylcyclohexyl moiety relaxivity increases 8 fold at 20 MHz
and 37 °C.40, 54 But these approaches have an added advantage of allowing the attachment
of multiple contrast agents to to be attached to each carrier, further increasing the
relaxivity both by slow tumbling of the Gd3+ chelate and an increase Gd3+ payload. The
binding scheme should be chosen carefully in order to attain the desired R value without
affecting the other more favorable properties of the Gd3+ ion complexes, such as the
water exchange rate 𝜏𝑀

Recently, the model free Lipari- Szabo approach has proved

useful in describing the rotational motion of macromolecule. Two kinds of motions are
assumed to affect relaxation: a rapid, local motion and a slower global motion. Even
though it is a crucial parameter, there is no direct method to measure R. It can be
obtained by fitting the data from 1H Nuclear Magnetic Relaxation Dispersion (NMRD)
profile.

1.4.9: Gd3+ water distance 𝑟𝐺𝑑−𝐻
T1M is proportional to 1/r6, as shown in Eqn 3 above, therefore varying the Gd3+-water
distance could lead to drastic enhancement of relaxivity. Decreasing the distance by
about 0.2 Å would increase relaxivity by 50%. Gd-H distances have been determined by
X-ray studies or calculated indirectly by relaxivity studies and they are generally in the
range of 2.5 Å-3.3 Å. The Gd–H distance for GdDOTA1- and GdDTPA2- derivatives has
been determined as 3.1 Å ± 0.1 Å by ENDOR spectroscopy.55,56
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1.5: Electronic relaxation 𝑇𝑖𝑒
Electronic relaxation for Gd3+ chelates is related to the zero field splitting of the
electronic spin states and its dynamic distortion.57

In a paramagnetic ion unpaired

electrons under going relaxation generate a flactuating magnetic field that causes nuclear
relaxation.58 This defines how efficiently the proton will be relaxed. For Gd3+ electronic
relaxation depends on the magnetic field applied and its importance decreases as the
magnetic field increases . Gd3+ has a symmetrical electronic configuration and this gives
rise to relatively slow electronic relaxation but for elements like Dy3+ (even though it has
a large magnetic moment) it is a a poor relaxation agent since the electronic relaxation is
fast.

1.6 Making 𝜏𝑅 longer by encapsulation
Nano assembled capsules (NACs) are structures in which polyanions and cationic
polymers are assembled into a stable closed structure encapsulated by a nano-particle
shell. It has been shown that GdDOTP5- can be employed as the polyanion in this system
and be trapped inside the capsule.59 This approach is attractive because formation of
aggregates occurs at very mild pH values and at room temperature; the nanocapsules self
assembly technique is extremely facile and quickly produces the nanoassembled
capsules; the technique is able to effectively slow tumbling of the Gd3+ chelate and
affords high per-Gd3+ relaxivity.60 NACs have been synthesized using different cationic
polymers such as polyallylamine hydrochloride (PAH), poly-L-lysine (PLL)61 and
polyethylenimine (PEI)62 and using multivalent anions such as phosphate citrate63,
EDTA64, indocyanine green65 and the chelate62 e.g. GdDOTP5-.62 Encapsulation within
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NACs affords larger gains in relaxivity when compared to the clinically available
chelates, the method comes with attractive features like the capability to modify the
surface by attaching targeting molecules on the surface of the nanoassembled capsules.
In addition it allows for the use of higher payloads of the chelate while at the same time
reducing molecular tumbling of the small chelates thereby increasing the relaxivity
values attained. The per Gd3+-relaxivity was found to be dependent upon the the size of
the NAC, smaller NACs afforded higher relaxivity. The size of the NAC can easily be
manipulated by changing the charge ratio R, which is defined as the ratio of the total
negative charge of the anion to the total positive charge of the polymer as shown below in
Eqn 10.62

[𝒂𝒏𝒊𝒐𝒏]𝒇𝒊𝒏𝒂𝒍 |𝒛− |
𝑹 =
[𝒑𝒐𝒍𝒚𝒎𝒆𝒓]𝒇𝒊𝒏𝒂𝒍 |𝒛+ |
Equation 10: Ratio of anion to polymer
1.7: Chemical Exchange Saturation Transfer
Chemical exchange saturation transfer (CEST) is a relatively new method for generating
image contrast, which holds a great promise in in vivo imaging. Unlike Gd3+ based MRI
contrast agents CEST agents require slow water exchange kinetics. CEST contrast is
generated by saturating of a pool of solute protons that are in chemical exchange with
bulk water protons but have a different chemical shift. Applying a low power radio
frequency pulse at the resonance frequency of the solute exchangeable pool saturates
these protons. Application of a radio frequency pulse B1 that is tuned to the frequency
offset of the solute proton pool leads to a net excitation of protons in the lower energy
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states into their higher energy states–this is called saturation. The number of protons at
each energy level will equalize and the proton pool will be saturated if the radio
frequency pulse has enough energy as shown in scheme 2. The most common pathways
of chemical exchange for CEST applications include proton molecular exchange, proton
exchange, or a combination of both. An example of proton exchange is when a proton
from an amide group moves to bulk water and an example of molecular exchange is
when a water molecule moves between free water and a paramagnetic lanthanide metal
associated with a paraCEST agents.

Scheme 2:Schematic representation of spins aligned with and against the field (upper
and lower energy levels, respectively) above simulated NMR spectra (below) for two
chemically distinct pools of nuclei (left), two spins after a saturation pulse has been
applied66
To observe CEST contrast chemical exchange should be slow to intermediate on the
NMR time scale
Equation11: Exchange regime for CEST
exchange rates
∆𝜔 ≥ 𝑘𝑒𝑥
Equation 11: Exchange rate for CEST exchange rates
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Systems with longer T1 values allow a larger range of viable exchange rates because the
longer T1 values allows the spins to maintain their magnetization longer. In paraCEST
the shift is due to lanthanide ions and each lanthinde affords a different ∆𝜔. The large
chemical shifts afforded by paramagnetic lanthanides allow faster exchange rates while
mantaining the slow exchange regime between the bound and bulk water molecule.67
Although  > 2ppm can help avoid direct saturation of water68, larger values of  can
eliminate this problem completely.

Figure1.12 : CEST spectrum; A CEST effect (or CEST peak) can be observed at 10 ppm
as highlighted with the arrow. The peak at 0 ppm is due to direct saturation of the bulk
water protons by the RF saturation pulse.59
A typical CEST MRI experiment consists of the acquisition of a series of MR images that
are each preceded by an RF saturation pulse with an incrementally different frequency.
The normalized MRI signal intensity is then plotted as function of the RF saturation
pulse frequency offset relative to the bulk water resonance to create a CEST spectrum. If
experimental parameters are appropriate then a reduction in MRI signal intensity referred
to as a ‘CEST peak’ may be observed in the CEST spectrum. The form of a CEST
spectrum is shown in Figure 1.12.the CEST peak at 10 ppm is highlighted by an arrow.
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CEST enables detection of approximately mM proton pools that are in exchange with
approximately 55 M concentrations of water.

The effects of chemical exchange

saturation transfer have been investigated for more than 50 years but in the context of
exogenous images agents for less than two decades. A modified version of the Bloch
equations known as the Bloch-McConnell equation that included the CEST effect was
introduced in 1957. The earliest example relating directly to CEST imaging was done by
Forsen and Hoffman in 1963. They measured hydroxyl proton transfer rates between
salicylaldehyde and water by placing a saturation pulse on resonance with solute protons
and recording the solvent signal intensity inorder to study chemical exchange. It was
Balaban and Ward in 2000 who coined the term CEST recently when they reported a new
class of MRI contrast agents that were sensitive to their environment. They investigated
applications of CEST agents to measure tissue temperature69 and pH.70-72 Now there are
many diverse CEST applications including cell labeling73 , monitoring glucose uptake74
detection of the ischemic penumbra following stroke75, detection of zinc ions76 and many
more.

1. 7.1: Diamagnetic CEST agents
Initially molecules used to generate CEST were diamagnetic molecules known as
diaCEST agents. DiaCEST was first reported using small molecules such as barbituric
acid77 diaCEST agents can be either endogenous or exogenous molecules such as
macromolecules, sugars, amino acids, glucosaminoglycans and heterocyclic compounds.
The major drawback of diaCEST agents is the small size of their ∆𝜔. DiaCEST agents
typically have  < 6 ppm and this both limits the permitted rates of exchange as well as
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pre-saturation power (in order to avoid direct off-resonance saturation of water.
Nonethelees diaCEST agents have been useful for exploring in vivo gene expression,
imaging the in vivo distribution of glycogen74,

78

, pH79,

80

and studying cartilage

degradation.81 The work on diaCEST has also been fundumental in discovering another
class of contrast agents known as the paraCEST agents.
1.7.2: Paramagnetic CEST agents
Zhang and Sherry were the first to demonstrate that these paramagnetic chelates can be
used for CEST imaging82. Initially paraCEST agents developed around paramagnetic
lanthanide ions. Lanthanides vary along the 4f period and each metal has a different
electronic structure and induce different hyperfine shift. The magnetic moment of the
lanthnaide influences the magnitude of interaction between external magnetic field and
magnetic moment. The magnetic susceptibility governs the lanthanide induced shifts
(LIS). These large shifts make paraCEST agents more advantageous than diaCEST
agents. These larger LISs () allow faster exchange rates between the exchangable
protons and bulk water without breaching the slow to intermediate exchange condition.
This allows more spins to be transferred within a particular time frame, potentially
increasing CEST.

T1 shortening contrast agents have at least one water molecule

coordinated to the paramagnetic center but the rate of exchange for these complexes is
much faster than the slow to intermediate exchange limit which is required for CEST
agents. Slower exchange rates have been found for DOTA-tetraamide derivatives, such
as DOTAM, where the acetate pendant arms have been replaced by acetamide arms. In
comparison to carboxylates, amides are weaker electron donors and therefore create a
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more electron deficient lanthanide center, leading to a stronger water metal interaction.
This ultimately slows water exchange.83,

84

The amide arms may also provide steric

hinderance at the metal centre, this may also contribute to a slowing of the exchange of
exchangable protons. The DOTAM ligand has been the elementary structure in the
subsequent synthesis of paraCEST agents85. Eu3+ of all the lanthanide metals has the
slowest rate of water exchange and a suitably low paramagnetic relaxation enhancement.
These are favourable properties in the design of paraCEST agents, an example of such an
agent is EuDOTAM-gly-Et.86 When Eu3+ is replaced with other lanthanide metals like
Tm3+~ 50𝑝𝑝𝑚, Dy3+ ~ 70𝑝𝑝𝑚, Tb3+ ~ 60𝑝𝑝𝑚 and Yb3+ ~ 16𝑝𝑝𝑚 and the chemical
shift from the bulk water changes too, these values depends on the metal chosen. CEST
MRI is relatively insensitive (even paraCEST) and often requires high concentration of
contrast agents. The CEST efficiency is proportional to the number of exchangeable
protons resonating at the same frequency per CEST molecule

1.8 Enhaning sensitivity of CEST agents
1.8.1: Polymeric systems
Increasing the number of exchangeable groups on the agent will make a CEST agent
more sensitive. This approach to improve CEST sensitivity has been investigated by
Pikkemaat87 and co-workers. They studied functionalized YbDOTAM 3+ chelates with
different generations of dendrimers of poly (propylene imine) and their applicability as
pH responsive paraCEST agents.

Wu and co-workers took a different approach

preparing a linear polymer using free radical chain polymerization of EuDOTA-4AmCE
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derivatives. The detection limit in both studies were found to be orders of magnitude
lower than the monomeric agents, but only linearly related to the number of metal ions.
Thus, one viable approach to increasing the sensitivity of CEST is to increase exchanging
sites associated with the agent.

1.8.2: Optimization of the exchange rate
One of the most important factors that affect CEST efficiency is the exchange rate. If the
exchange rate is too fast the exchanging site cannot be activated and if the exchange rate
is too slow there will be inefficient transfer of saturated spins, both of which will
decrease the CEST effect. There is an optimal exchange rate for each exchanging site of
a CEST agent and this optimal rate has been found to be dependent on the saturation
power as well as the shift difference . Higher saturation powers allows one to use fast
water exchange rate, however for clinical application, the amount of power used is
limited, and this limits the use of fast water exchanging systems. Therefore the design of
CEST agents is focused on slower water exchange rates.

Water exchange rate in

paraCEST agents can be altered by altering the coordination geometry this depends on
the type of isomer whether it is a square antiprism (SAP) or a twisted square antiprism
(TSAP)84, 88 and ionic radii89, 90, changing the lanthanide91 and the chemical environment
and the chemical environment is the polarity92, 93 and the steric bulky of the side arms94.
A lot of these parameters have been thoroughly explored in trying to optimize the water
exchange rate of CEST agents; however, none afford the kinds of gains necessary to
drive down detection limits to the extent needed for practical in vivo use.
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1.8.3: Nano systems
One strategy that has been used to optimize the CEST effect is nano systems, which have
great promise owing to their high surface to volume ratio. One of the major strategies
which have been used to increase the sensitivity of CEST agents is the encapsulation of a
chemical shift reagent, e.g. TmDOTMA, inside a liposome. The encapsulated water
molecule is then shifted away from the bulk water signal.

Two water signals are

observed on the NMR spectrum for these systems, the intra-liposomal water is shifted 3.1
ppm downfield from the bulk water. This intra-liposomal water gives rise to CEST
because exchange across the phospholipid membrane is slow. Lanza and co-workers
incorporated a bifunctional paraCEST agent on the surface of perfluorocarbon
nanoparticles for molecular imaging; this increased the number of water exchanging
sites.95,

96

Although, this system provides a large increase in payload and it does not

compare with the liposome systems since the CEST effect again scales linearly with the
number of chelates incorporated.
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Chapter 2. Nanoassembled Capsules:A Versatile Platform for developing molecular
imaging agents
2.1: Introduction
Magnetic resonance imaging (MRI) has many attributes that make it ideal for molecular
imaging.

It has high spatial resolution and excellent soft tissue contrast and high

resolution anatomical images can be obtained without radioactive tracers or ionizing
radiation. The difference between the relaxation rate constants of normal and diseased
tissues can be small and to generate contrast between these tissues contrast agents are
sometimes used97, 98. However, the relaxivity of the clinically available contrast agents is
poor, normally 3-5mM-1s-1 (25 MHz , 25℃)20,

99, 100

and they are non-specific being

delivered differently to tissue based on diffusion and vascular characteristics. This means
that the applications of these contrast agents are limited. The low detectability arising
from low relaxivity means that, high doses are often required of Gd3+ chelates (0.1 mmol
kg-1)101. This poses a problem for visualization of specific biomarkers of disease by
molecular imaging, since these biomarkers are present at much lower concentrations
usually in the micromolar range. Hence increasing the detectability of MRI contrast
agents is the key to developing MR based molecular imaging applications. This can be
achieved by increasing the relaxivity of the contrast agents by optimizing structural and
dynamic properties or by increasing the accumulation of contrast agents to the site of
interest. Nano assembled capsules (NACs) are one way of achieving both of these goals.
Wong and co-workers developed a nano encapsulation method in which negatively
charged nanoparticles, cationic polymers and multivalent anions are combined to
generate silica/polymer nanocapsules.64, 102, 103 The synthesis of these nanoparticles is a
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two step method where a cationic polymer and a polyanion104 are added together in
solution to form an aggregate. An aqueous suspension of SiO2NPs is added to form a
shell around the aggregate.

Scheme 3: A Schematic representation of the preparation of nano assembled capsules
which are SiO2-NP-coated
The work of Wong and co-workers was extended to the development of contrast agents
by Plush et al.: NACs were prepared using the polyanionic chelate GdDOTP5- and
pollyallyl amine hydrochloride (PAH) as the cationic polymer, followed by encapsulation
with SiO2NPs62.

The encapsulation of GdDOTP5- was found to afford significant

increases in relaxivity and various synthetic parameters were found to offer good control
over the size of the NACs produced. GdDOTP5- relaxivity arises mainly from the second
sphere of water molecules formed through hydrogen bond interaction between the
phosphates and the water molecules from the bulk water.105-107 Phosphonates are better
second hydration sphere generators compared to carboxylates.

For GdTTHA3- the

contribution is entirely from the outer hydration sphere as a free chelate. Even though all
four chelates do have some outer hydration sphere contribution of about 1.8 mM-1s-1 (20
MHz, 25 ℃)107,

108

to the overall observed relaxivity of the chelates. GdDOTA1- and

GdDTPA2- are inner sphere chelates and their primary relaxivity contribution arises from
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the inner hydration sphere, where the relaxivity arises mainly from the exchange of the
inner hydration sphere water molecule with the bulk water. The inner sphere contribution
to relaxivity is approximately 2.9 mM-1s-1(20 MHz, 25℃).109 hence as free chelate
GdTTHA3- has a very low relaxivity compared to the other carboxylates. NAC synthesis
was performed using the synthesis method which was previously reported62.

Scheme 4: The structures of the chelates investigated in this work16 GdDOTA1-,
GdDTPA2-, GdTTHA3-, and GdDOTP5Although these results are encouraging, it was unclear to what extent this encapsulation
strategy can be applied to other chelates, in particular those with charges lower than 5-.
To do so we investigated the encapsulation with the following chelates GdDOTA1-,
GdDTPA2-, GdTTHA3-, GdDOTP5- which are, monoionic, diionic, triionic, and
pentaionic chelates, respectively62. This choice of chelates also allows another effect to
be studied: the effect of encapsulating chelates with different hydration states.
GdDOTP5- chelate which does not contain a coordinated water molecule (q = 0), the
chelates GdDOTA1- and GdDTPA2- are q = 1 and this could afford higher relaxivity. The
idea was to use these negatively charged chelates as salts, to form aggregates with a
positively charged polymer (PAH) upon mixing and coat this aggregate with silica
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nanopaticles as the shell material. Formation of Gd-NACs through self assembly is
shown in Scheme 3.

2.2: Experimental
2.2.1: Materials
Poly(allylamine hydrochoride),(PAH, 56 000g/mol) ~596 allylamine units per molecule
were purchased at Sigma Aldrich, collodial SiO2NPs was purchased at Nissan chemicals
and H8DOTP was purchased from macrocyclics Dallas,TX,USA.

GdDOTA1-,

GdDTPA2- GdTTHA3-and GdDOTP5-108, 110, 111 were prepared as previously published.112,
113

The concentration of the chelates was adjusted to a pH of 9 with 1M NaOH. The

SiO2NPs solution was diluted to a concentration of 2 wt % by adding 1mL of the 20.3 wt
% collodial solution in water to 9mL of acetonitrile.
2.2.2: Synthesis of Nanoassembled capsules
A (3/2 MeCN/H2O) PAH solution (20𝜇L, 5mg/mL)was mixed with a (3/2 MeCN/H2O)
Gd3+ solution (120𝜇L) in an eppendorf tube and was vortexed at a low speed. A turbid
solution immediately resulted indicating the formation of a polymer-chelate aggregate;
the aggregates were then aged for 10 minutes. Diluted SiO2NP suspension (2 wt% in
MeCN) was added,and the resultant mixture was vortexed at a medium speed. R charge
ratios of 0.3, 0.5, 0.75, 1.0, 1.25 were studied in this work. It is defined as the ratio of
total number of negative charges from the Gd3+ chelates to the total number of positive
charges from the polymer as shown in equation 2.1114.
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(2.1)

A turbid solution immediately resulted, indicating the formation of polymer-anion
aggregate. The aggregates were aged for 10 minutes before the SiO2NPs suspension was
added. The resultant mixture was vortexed at a medium speed. The precipitate was
recovered through centrifugation.
2.3: Characterization
2.3.1: Dynamic light Scattering
Hydrodynamic light scattering was carried out with Horiba (Irvine,CA,USA) LB550
dynamic light scattering instrument. It has an autocorrelator at a laser wavelength of 650
nm.

All studies were carried out at a 90° scattering angle ,and were temperature

controlled at 25℃ in polystyrene cuvvetes. Freshly syringed samples were dispersed in
water and measured at four dilutions to ensure size distributions were independent of
concentration effects.

Samples were regularly agitated to prevent settling of larger

particles.
2.3.2: Scanning Electron Microscopy
SEM was carried out using a FEI, equipped with secondary electron, X-ray (EDX)
detectors. Secondary electron images were taken at 5kV with a working distance of 5–10
mm. A droplet of NACs suspension was placed on the aluminum stub and dried in air.
The sample was then sputter coated with gold for 55 seconds.
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2.3.3: Relaxometry
Longitudinal water proton relaxation T1s were measured on a 0.47 T Bruker Biospin
(Billerica, MA, USA) MiniSpec contrast agent analyzer operating at 19.99 MHz using an
inversion recovery pulse sequence. NACs were suspended in water (1 mL) at Gd3+
concentrations ranging from 0.22 mM to 2.37 mM. Samples were regularly agitated to
guard against settling of larger particles. Relaxivity values were determined in Excel by
linear regression analysis of the experimentally determined R1 values as a function of
Gd3+ concentration.
2.3.4: ICP-OES Gd3+ concentration determinations
Concentration determination of Gd was performed using a Perkin Elmer (Waltham, MA,
USA) Optima 2000 inductively coupled plasma optical emission spectrometer (ICPOES). Gd3+ standards were produced by quantitative serial dilution of a commercial 1000
mgL-1 gadolinium in 2% nitric acid standard (Fluka Analytical) into a 0.1% nitric acid
solution. Samples were prepared by digesting the dried samples with 70% HNO3
(100 μL) and water (900 μL). The resulting analyte was vortexed thoroughly, and then
filtered to remove any particulate using a 0.2 µm filter to produce the final sample for
ICP-OES analysis. Sample analyte concentrations were calculated to fall in the middle of
the constructed ICP-OES Gd3+ calibration curve to ensuring, accurate Gd spectral
readings. Readings were taken in triplicate and averaged. The highest percent relative
standard deviation allowed between these replicates was 1%, to ensure precise Gd3+
spectral readings for the samples analyzed in this work. The concentration of Gd3+ was
determined for each sample and then multiplied by the dilution factor.
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2.4: Results and Discussion
The size of the NAC and per Gd3+ relaxivity were found to be inversely related. For the
benefit of our research it was desirable to keep certain synthetic variables, such as solvent
and cationic polymer, fixed. The effect of varying the polymer used for aggregate
formation has already been explored by Plush and co-workers.62 The nature of the
polymer was found to have an effect on the size of the NACs attained and polly allyl
hydrochloride amine was found to give smaller NACs compared to the other polymers
studied. Smaller NACs afforded higher per Gd3+ relaxivities, therefore for this work only
PAH was used for NAC synthesis. In all experiments in this chapter the solvent mixture
used was 3:2 v/v aetonitrile and water mixture. Stock solutions of the chelate Gd3+and
polymer were prepared in 3:2 v/v of acetonitrile and water. In all cases, upon addition of
the anionic chelate the solution became turbid except for cases in which the anion was
GdDOTA1-. The reaction were stirred vigorously for 15 seconds, the aggregate was aged
for ten minutes, and then SiO2 nanoparticles in 100% acetonitrile was added. The
addition of SiO2 nanoparticles as the aggregate coating was crucial because the SiO2
nanoparticles stabilize the polymer chelate aggregate.

To ensure that there was no

distortion on the relaxivity measurements by any non-encapsulated Gd3+ chelates the
NACs were put through a series of centrifuge cycle washes in 10 kDa MWCO centrifugal
filter units. The constitution of the 2 wt % SiO2 nanoparticles stock suspension was
found to be critical to the formation of NACs; if the SiO2 nanoparticles were suspended
in water alone, or a 3:2 v/v MeCN/H2O mixture, then NAC formation was not observed.
NACs were characterized using dynamic light scattering for size analysis.

It was
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observed that as the charge ratio R increased the average size of the NACs was observed
to increase independent of the chelate being studied.

Figure 2.13: The effect of changing the R value on the average hydrodynamic diameter
of the NACs produced for GdDTPA2- (purple), GdTTHA3- (red) and GdDOTP5- (green).
Dashed lines are a guide to the eye only; error bars represent the 1st standard deviation
of the size distribution of the capsules. Sizes and their distributions are the average of 6
NAC preparations115
There was no general relationship between the size of the NACs and the charge ratio
observed across all the three chelates studied.

The size of NACs encapsulating

GdDTPA2- and GdDOTP5- was observed to increase sublinearly with increasing R value
even though structural relationship is not identical between these two chelates.

In

contrast, for NACs encapsulating GdTTHA3- the size of NACs seemed to increase
superlinearly with increasing R (Figure 2.13). On a structural basis, this observation is
difficult to explain. The only notable difference in structure is that GdTTHA3- unlike
GdDTPA2- and GdDOTP5- it has one uncoordinated carboxylate.

So, one possible

explanation is that while the charge on GdDTPA2- and GdDOTP5- is well distributed on
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the chelate, part of the charge on GdTTHA3- is concentrated on one of the carboxylates;
this may alter the interaction of the chelate and the cationic polymer..

Figure 2.14: SEM images of NAC preparations in 3:2 v/v MeCN/H2O with PAH and: A)
GdDOTA1- R = 1.0; B) GdDTPA2- R = 0.75; C) GdTTHA3- R = 0.75; D) GdDOTP5- R =
0.75
The production of NACs was apparent from the SEM images on Figure 2.14 of capsules
which have been shown to withstand several rounds of centrifuge without losing its
structural integrity.

GdDTPA2-, GdTTHA3- and GdDOTP5- are capable of forming

aggregates with the polymer in a way that will allow NAC formation. Furthermore, the
monoionic GdDOTA1- appears incapable of aggregation in a manner that allows NAC
formation. It was shown by Wong and co-workers that monovalent acetate could not
ionically cross link polymer chains, this was confirmed by Monte Carlo simulations,
where higher valent salt caused polymer to be in a collapsed or condensed form114, 116
hence increasing the ability of the polymer to cross link with the multivalent anion. The
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incorporation extent of Gd3+ chelate was determined using ICP-OES were the NACs
were digested using 15.7 M nitric acid. The concentration of Gd3+ was measured in both
the supernatant and the NAC. Overall there was greater than 99% incorporation of the
Gd3+ chelates achieved for NACs from all the chelates, though a lower percentage value
was observed for chelates like GdDTPA2- which had >93% incooperation as shown in
table 2 , For GdDOTA1- no further studies were performed because there was no
consistency in the formation of NACs. The per Gd3+ relaxivity was calculated using the
regression analysis by plotting the longitundal relaxation rate constant (determined by
inversion recovery) against the concentration of the Gd3+: the gradient is the relaxivity.
The effect of changing the R value on the per Gd3+ relaxivity is shown in Figure 2.15.
These results are braodly similar to those observed previously with GdDOTP5- and PAH
NACs in a different solvent mixture: as the R value is increased the per-Gd3+ relaxivity
decreases. In all cases the smaller the NAC size the higher the per Gd3+ relaxivity
observed.62
In comparison the GdDTPA2- continaing NACs have a lower relaxivity of the same R
value (0.3), even though it is a q = 1 chelate. Hence, it seems that the contribution of the
inner hydration sphere seem to be masked upon encapsulation. Encapsulation of q = 1
chelate did not seem to have an effect on relaxivity as was suggested in comparison to the
effect it had on q = 0 chelates and GdDOTA1- of a lower valence 1 could not afford to
form aggregates with the polymer therefore no further studies were perfomed on
GdDOTA1-. Encapsulation of chelates do have an effect on the overall relaxivity attained
by these chelates in comparison to the relaxivity of free chelates, NACs had higher
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relaxivity values even for larger capsules which had lower relaxivity values, they still
attained higher or equal relaxivity values compared to the free chelates as shown in Fig
2.13.

Figure 2.15: The effect of changes in the overall Gd3+ chelate charge on the relaxivity of
the NACs produced for different R values

Figure 2.16: Relaxivity values measured at 0.47 T at 25 ° C of encapsulated Gd chelates
compared to the relaxivity values of the free chelates
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Table 2: Summary of the variations in size and relaxivity arising from changing the
chelate charge and R value during the preparation of NACs.
Chelate

R value

% Gd3+ incorpa

Diameter nmb

𝒓𝟏 mM-1s-1 c

GdDTPA2-

0.30

99.7

127 ± 58

23.3 ± 0.3

0.5

94.5

645 ± 267

14.9 ± 0.1

0.75

93.3

1088 ± 232

8.5 ± 0.05

1.0

99.0

1542 ± 465

7.8 ± 0.01

1.25

99.9

1802 ± 581

4.8 ± 0.1

0.3

99.6

105 ± 60

22.7 ± 0.1

0.5

99.9

180 ± 110

14.0 ± 0.1

0.75

99.9

370 ± 260

7.4 ± 0.3

1.0

99.0

1100 ± 500

7.1 ± 0.3

1.25

99.9

1651 ± 445

6.5 ± 0.1

0.3

99.9

320 ± 260

46.4 ± 0.3

0.5

99.1

620 ± 235

19.8 ± 0.1

0.75

98.9

1147 ± 368

15.8± 0.1

1.0

98.6

1232 ± 650

7.1 ± 0.1

1.25

99.5

1598 ± 401

6.3 ± 0.2

GdTTHA3-

GdDOTP5-

1.
2.
3.

a

The percentage of Gd3+ chelate added to the NAC synthesis that was found to be incorporated
into the NAC.
b
The mean average hydrodynamic diameter of 6 NAC preparations ± the 1st standard deviation of
the size distribution, determined by dynamic light scattering.
c
The mean longitudinal relaxivity of 6 NAC preparations ± the 1st standard deviation, determined
at 20 MHz and 25 °C.115
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The relaxivity attained using highest R charge ratios, which produced large NACs, was
much lower and was independent of the chelate used to synthesize the NACs.

In

comparison to the NACs containing carboxylates chelates (GdDTPA2- and GdTTHA3-),
the NACs containing GdDOTP5- had a substantially higher relaxivity compared to the
slightly smaller NACs produced from the carboxylates containing chelates. This is
probably due to the known promotion of the strong second sphere interaction of the water
molecules with the water molecules from the bulk water and the phosphonate groups of
GdDOTP5- more than the carboxylates groups this tend to compensate the contribution
from the inner hydration sphere hence GdDOTP5- attained higher relaxivity.
Encapsulation has effectively reduced the molecular tumbling of these chelates and the
water molecules tend to be bound in the second sphere increasing water exchange rate
and reducing 𝑟𝐺𝑑𝐻 . Increasing the distance of the water molecule to the metal centre
from the inner hydration sphere has a major effect on relaxivity given that the rotational
correlation time is reduced. Upon encapsulation of the carboxylate chelates GdDTPA2the exchange of inner sphere water molecules is extremely slow or the exchange is so
insignificant that its contribution to overall relaxivity attained is not observed, hence the
overall contribution of the inner hydration sphere relaxivity on GdDTPA2- does not show
in its relaxivity which is similar to that of GdTTHA3- a chelate without a coordinated
water molecule. For these reasons encapsulation has a greater effect on the relaxivity of
GdTTHA3- than that of GdDTPA2-. GdTTHA3- has a relaxivity of just 2.65 mM-1s-1 as a
free chelate arising primarily from an outer sphere contribution,35 but showed
approximately 8.6 times increase in relaxivity for R = 0.3 NACs (Figure 2.16). This
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increase in relaxivity of GdTTHA3- could be attributed to a magnification of the second
sphere effect upon encapsulation of GdTTHA3-therefore an abrupt increase in relaxivity
was observed for this chelate relaxivity. We speculate that inside the NAC water is
comparativiely scarce and therefore water in the inner hydration sphere of GdDTPA2- is
unable to freely exchange and this mechanism contributes insignificantly to the overall
relaxivity. Proton exchange113 may be a more important mechanism for the transfer of
relaxation from the chelate to the bulk rather than the whole water molecule diffusing
between the bulk water and NAC interior.

2.5: Conclusions
In conclusion, encapsulation of Gd3+ chelates is a robust and versatile method to
synthesize high payloads of contrast agents, and attain very high relaxivity values without
expensive modification to the contrast agents. Lower charge densities like 2- were well
tolerated in the synthesis of NACs, they formed capsules for all the R values studied in
this chapter but charge of -1 could not form a consistency formation of capsules. As was
shown by Wong and co-workers that monovalency acetate could not ionically cross link
polymer chains, this was confirmed by Monte Carlo simulations, where higher valent salt
caused polymer to be in a collapsed form hence better interaction with the polymer.
Therefore a dependence on charge was observed the lower the charge of the chelate the
less the interaction of the chelate with the polymer because for lower charge density, less
turbid solution were observed for the chelate GdDTPA2- compared to the turbidity
observed for GdDOTP5-of the same charge ratio, therefore charge do have an effect on
the formation of the aggregate. The ability of a chelate to form an aggregate with the
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polymer has a profound effect on the rigidity attained to reduce molecular tumbling on
the chelate hence higher charge density tend to have a better interaction with the polymer
hence better rigidity attained by higher charges compared to lower charges as was shown
by the relaxivity values attained by smaller capsules which have better interaction with
the polymer on forming the aggregate hence better reduction in molecular tumbling in
solution of the small chelates. Size of the NACs was affected by the R value and cation
employed, there was a general trend that the smaller the R value the smaller the size of
the NACs produced. Encapsulation of GdDTPA2- a q = 1 chelate did not show to
enhance the relaxivity attained by this chelate, GdDOTP5- and GdTTHA3- q = 0 chelates
had very competetive relaxivity values, which we speculated that this could be that upon
encapsulation the contribution from the inner hydration sphere becomes scarce therefore
its effect is not observed in the per Gd3+ relaxivity attained from the q = 1 chelates. In
this work we observed that the smaller the NAC the better the restriction in tumbling of
the chelates hence higher per Gd3+ relaxivity for smaller NACs compared to their larger
counterparts. Encapsulation of Gd3+ chelates allows high payload delivery of these
chelates and therefore an increase in relaxivity especially for targeted MR imaging where
T2-shortening iron oxide contrast agents are used at lower concentrations. This work
shows that encapsulation of Gd3+ chelates increases relaxivity values by reducing
molecular tumbling and can also deliver high payloads of the imaging agent this may
decrease limits of detection to levels at which biomarkers for disease pathology exist. .
In addition to slowing the tumbling of the chelates by forming an aggregate with the
polymer, when designing a contrast agent for MRI one must ensure that water molecules
associated with the NAC have access to bulk water as this is critical to the function of an
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MRI contrast agent. For this reason making smaller NACs is crucial for achieving the
highest per-Gd3+ relaxivity.

In these smaller NACs encapsulation allows sufficient

movement of water protons to allow an enhancement in relaxivity for all chelates. Annah
is

the

coolest

ever!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

53
Chapter 3. An Alternative Coating Method for the High Payload Synthesis of Nano
Capsule MRI Contrast Agents
3.1.1 Introduction
We have demonstrated that NACs represent a versatile and robust platform that may
allow the dvelopment of targeted MRI contrast agents for molecular imaging applications
with very low detection limits. However, concern must remain about the in vivo stability
of these capsules with their shells that are held togather solely by electrostatic forces.
One possible solution to this problem may be the use of capsules that also contain a high
payload of a Gd3+ chelate encapsulated within a covalently linked shell. Capsules should
incorporate as many contrast agents as possible into a single capsule to facilitate the
delivery of large payloads to a pathology of interest in targeted imaging applications.
Stucky and co-workers reported the same synthesis approach.117 These spheres are called
nano-assembled capsules (NACs). The synthesis of NACs is rapid and it occurs under
ambient conditions at mild pH values.62 Synthesis method of NACs have been used to
encapsulate a clinical florescent probe indocyane green102 and GdDOTP5-62 an MR
contrast agent and had a significant enhancement on relaxivity of GdDOTP5-. In another
work we published a series of Gd3+ chelates where encapsulated in these capsules and
there was a significant increase in relaxivity of these chelates, attaining relaxivity value
of 46.3 mM-1s-1 for chelates of GdDOTP5- R = 0.3 which is ten times more than the
relaxivity value of the free chelate.115

The NAC synthesis method has advantages

compared to other synthetic methods of increasing a high payload of metal centres
because it is performed at room temperature and is synthetically straight forward. The
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polyanionic Gd3+ chelates are mixed with a solution of a polymer in a mixture of a
organic/aqueous solution and forms an aggregate which is encapsulated with an SiO2NPs
to form a NAC. The formation of NACs is driven by the electrostatic attraction of the
ions involed. Due to this ectrostatic attraction this tends to raise questions on how robust
these NACs are in vivo, hence need to devise another route to synthesize an alternative
coating method.

A new encapsulation method was employed

which uses peptidic

linking to form the capsule shell. Herein we describe the development of Crosslinked
Assembled Capsules (CACs) that are prepared firstly by mixing the polymer solution and
a poly anion to form an aggregate in the same manner as for NACs. The surface of the
aggregate is covered with primary amines which could be used to form peptidic bonds
with a dicarboxylic acid, such as succinic acid,to coat and crosslink the surface with a
peptide coupling reagent (EDC). This encapsulation method used was investigated with
a view to produce CACs encapsulating GdDOTP5-. The initial stage of synthesis of this
work was performed using PAH and pyrophosphate solutions and glutamic acid was used
to coat the aggregate and EDC for cross linking.
3.1.2 Experimental
Water refers to deionized water with a resistivity of 18.2 M. All solvents and reagents
were purchased from commercial sources and used as received unless otherwise stated.
Pollyallylamine hydrochloride (PAH) (56,000 MW), poly-L-lysine (50,000 MW), Lglutamic acid, succinic acid and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)
were purchased from the Sigma-Aldrich corporation and used as received. H8DOTP was
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purchased from Macrocyclics. GdDOTP5- was synthesized by previously reported
methods.108, 110, 118.

Scheme 5: Schematic of synthesis of cross linked assembled capsules versus that of
NACs
3.1.3 Synthesis of CACs with Simple Diamagnetic Anions
Stock solutions of polymer and anion were prepared in 100% water at pH 9. Stock
solution concentrations were as follows: (polymer) = 89 µM, (citrate) = 4.2 to 19.9 M and
(pyrophosphate) = 2.9 to 14.9 M. The polymer (20 μL) and anion (120 μL) stock
solutions were then added to water (10 mL) at pH 9. The charge ratio R was varied by
varying the initial concentration of anion. After mixing the reaction immediately became
turbid reflecting the formation of a polymer-anion aggregate. The solution was vortexed
at low speed for 10 s and then aged for 3 minutes without agitation. After aging, a
solution of dicarboxylic acid (20 μL, 0.089 M) was added. Succinic acid or L-glutamic
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acid were used at identical concentrations. The solution was gently mixed and then aged
for 3 minutes. A solution of 1-ethyl-3-(3-dimethylaminopropyl carbodiimide (20 µl,
0.174 M) in H2O was then added, gently mixed and aged for 30 minutes. The reaction
was then gently centrifuged, the supernatant removed and the capsules recovered by
resuspension in water.
3.1.4 Synthesis of Gd3+-containing CACs
An 8.9 µM stock solution of PAH was prepared by dissolving PAH (0.0498 g, 0.89
µmol) in a 3:2 v/v mixture of acetonitrile and water (10 mL). A stock solution of
GdDOTP5- was prepared by diluting a concentrated solution into a 3:2 v/v mixture of
acetonitrile and water to afford a 0.757 mM stock solution. The pH of the chelate stock
solution was adjusted to 9, by addition of 1M NaOH solution. Stock solutions of EDC
(0.174 M) and succinic acid (0.089 M) were prepared in pure water. For CACs R = 0.5,
stock solutions of the polymer (20 µL) and GdDOTP5- (120 µL) were added to a stirred
solution of 3:2 v/v MeCN/H2O (1 mL). Upon addition of the chelate stock solution the
reaction rapidly became turbid. The reaction was vortexed at a medium speed for 10
seconds. Aggregates were then allowed to age for 3 minutes before addition of the
succinic acid stock solution (20 µL). The reaction was vortexed for a further 10 seconds
at medium speed and then allowed to age without agitation for 3 minutes. A solution of
EDC (20 µL) was added and the reaction was aged for 1 hour. Unreacted starting
materials were removed by filter centrifugation using 10 kDa MWCO filter centrifuge
tube. The CACs retained in the filter centrifuged tube were washed with water and
filtered by centrifugation for 30 minutes at 9,000 rpm a total of six times. The CACs
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were then taken up into water (1 mL) and recovered into a sample vial. All CAC
preparations were repeated six times and data are an average of all of these independent
capsule preparations.
3.1.5 Scanning Electron Microscopy
Scanning electron microscopy (SEM) was performed on a FEI Sirion FEG electron
microscope equipped with an energy dispersive X-ray (EDX) detector. A droplet of
NACs suspension was placed on the aluminium stub and dried in air, the sample was then
sputter coated with gold for 55 seconds. Secondary electron images were taken at 5kV
with a working distance between 5-10mm.
3.1.6 Transmission Electron Microscopy
Transmission electron microscopy (TEM) imaging was performed using carbon/copper
TEM grids on a JEOL 1200 EX system with an accelerating voltage of 40 to 120 kV and
mounted with a Sis Morada 11 Mpixel CCD camera.
3.1.7 Confocal microscopy
Confocal images were captured using a TCS-SPE II Leica DM 2500 with 63X
magnification and a laser excitation wavelength of 488 nm for FITC an excitation
wavelength of 500 nm and emission wavelength 555nm. Scan format was 512 X 512
pixels. Samples were mounted on conventional glass slides and sealed under cover slip
to prevent drying
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3.1.8 Light Scattering
Dynamic light scattering was performed on a Horiba LB-550 dynamic light scattering
instrument. For these measurements freshly syringed filtered samples were dispersed in
water and measured at four dilutions to ensure size distributions were independent of
concentration effects. Samples were regularly agitated to guard against settling of larger
particles.
3.1.9 Relaxometry
Water proton T1s were measured on a 0.47 T Bruker MiniSpec contrast agent analyzer
operating at 19.99 MHz using an inversion recovery pulse sequence.

NACs were

suspended in water (1 mL) at Gd3+ concentrations ranging from 0.22mM to 2.37 mM.
Samples were regularly agitated to guard against settling of larger particles. Relaxivity
values were determined by linear regression analysis of the experimentally determined R1
values as a function of Gd3+ concentration in Excel.
3.1.10 ICP-OES Gd3+ Concentration Determinations
Concentration determination of Gd was performed using a Perkin Elmer Optima 2000
inductively coupled plasma optical emission spectrometer (ICP-OES). Gd3+ standards
were produced by quantitative serial dilution of a commercial 1000 mgL-1 gadolinium in
2 % nitric acid standard (Fluka Analytical) into a 0.1% nitric acid solution. Samples
were prepared by digesting the dried samples with 70% HNO3 (100 µL) and water (900
µL). The resulting analyte was vortexed thoroughly, and then

filtered to remove any

particulate using a 0.2µm filter to produce the final sample for ICP-OES analysis.
Sample analyte concentrations were calculated to fall in the middle of the constructed
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ICP-OES Gd3+ calibration curve to ensure accurate Gd spectral readings. Readings were
taken in triplicate and averaged. The highest percent relative standard deviation allowed
between these replicates was 1%, to ensure precise Gd3+ spectral readings for the samples
analyzed in this work. The concentration of Gd3+ was determined for each sample and
then multiplied by the dilution factor.

3.1.11 Results and Discussions
The first step of the CAC preparation is identical to that of NACs. An initial preparation
of CACs was performed using pyrophosphate as anion and PAH as the cationic polymer
to form an aggregate in pure water at a mild pH by Sally Plush. L-Glutamic acid was
then used to create a coating of the surface of the aggregate, interacting with the free
amino groups that are available on the aggregate surface. The coated aggregates were
then crosslinked by addition of a peptide coupling reagent 1- ethyl-3-(3-dimethylamino
propyl) carbodiimide (EDC). Capsules were purified by centrifugation and resuspendend
in water. TEM images show the presence of the capsules as shown in Figure 3.17. This
new approach to encapsulation was investigated in terms of its ability to encapsulate Gd3+
chelates. The same methodology was employed to encapsulate GdDOTP5-, which was
mixed with PAH (the cationic polymer) in 3:2 MeCN/H2O at pH 9. R ratios from 0.3 to
1.0 where investigated and in each case a turbid solution rapidly formed a sign of the
formation of an aggregate. Succinic acid was used as the coating dicarboxylic acid on the
surface of the aggregate. EDC was used, as before, as the cross linker. After purification
by centrifugation through a 10kD MWCO centrifuge filter Gd3+-containing CACs were
obtained. Formation of CACs is shown on the SEM images Figure 3.17.
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Figure 3.17: Electron micrographs of different stages of CAC preparation. A) TEM
image of a single pyrophosphate/PAH aggregate (R = 5) showing the loose morphology
of the aggregate; B) TEM image of a pyrophosphate/PAH aggregate with a glutamate
coating showing the tighter surface morphology of the coated aggregate; C) TEM image
of a pyrophosphate/PAH CAC after treatment with EDC showing the crosslinked capsule
shell; and SEM images of GdDOTP5-/PAH CACs after treatment with succinic acid and
EDC D) R =0.5 and E) R = 1.
The hydrodynamic diameter of the CACs was determined by dynamic light scattering.
The size of CACs was found to be dependent on the charge ratio R in a similar way to
NACs: the smaller the R value the smaller the CACs observed and vice versa.
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Figure 3.18: A comparison of CACs (red) and NACs (green) prepared using PAH and
GdDOTP5- average diameter. Each value is the mean of six nano capsule preparations

Figure 3.19: A comparison of CACs (red) and NACs (green) prepared using PAH and
GdDOTP5- contrasting the per Gd3+ longitudinal relaxivity (20 MHz and 298 K). Each
value is the mean of six nano-capsule preparations

The smallest capsules were attained (R = 0.3) from this method were almost half the size
of the NACs produced using the same value of R and chelate (GdDOTP5-) as shown in
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Figure 3.18. It is notable that the trend for the size of NACs and CACs observed as R
changes is not identical, although CACs are smaller than NACs when prepared with low
R values they are slightly larger than NACs when higher R values are employed.

The smaller size of R = 0.3 CACs versus NACs has a substantial impact on relaxivity.
The measured relaxivity, 70.2 mM-1s-1 (20 MHz, 25 C) represents an almost 2-fold
enhancement in relaxivity over the NACs (Figure 3.19) and a 15-fold enhancement over
GdDOPT5- alone. In all cases the per Gd3+ relaxivity correlated with the size of the
capsule formed; as the charge ratio increases there was a decrease in relaxivity and an
increase in size of capsules (Figure 3.19). The larger the capsule size the longer the
distance the proton close to the chelate has to diffuse to exchange with bulk water. The
higher relaxivity values found for CACs relative to NACs, even in the case of R = 1.0 (in
which the CAC is larger than the NAC) is an indication that the cross-linked coating of
CACs is and least as, and probably more, permeable to water than the SiO2NP shell of
NACs. Interaction of the GdDOTP5- with the cationic polymer PAH in the aggregate is
anticipated to limit the tumbling of the chelates in solution; this is the cause of the large
increase in overall relaxivity. Smaller capsules have higher relaxivity compared to larger
capsules because proton (or whole water) exchange between the chelate and bulk water is
faster (diffusion being proportional to the reciprocal of the diameter).

GdDOTP5-

aggregated into larger capsules do not have such high relaxivity values which shows that
encapsulation does play a role in limiting diffusion of water proton even though a robust
shell for encapsulating is needed if these nano assembled capsules are to be used in vivo.
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Table 3: The average hydrodynamic diameter (m) determined by dynamic light
scattering of GdDOTP5- containing nano capsules (CACs and NACs) prepared with PAH
in 3:2 MeCN/H2O as a function of the R value used in their preparation. Data are
presented with the 1st population standard deviation
CACs

NACs

% Gd incorp

R = 0.3

0.127 ± 0.057

0.32 ± 0.26

99.2

R = 0.5

0.265 ± 0.138

0.62 ± 0.235

98.7

R = 0.75

0.863 ±0.488

1.147 ± 0.368

98.6

R = 1.0

1.534 ± 0.58

1.232 ± 0.65

99.5

The percentage encapsulation of GdDOTP5- into CACs was found to be ≥ 98%,
comparable to the rate of incorporation into NACs. The high rate of incooperation of
GdDOTP5- into these capsules is correlated to the efficient interaction of GdDOTP5- with
the polymer PAH which in turn afford high payloads of the chelate per capsule.

3.1.12: Probing the stability of cross linked assembled capsules (CACs)
A synthesis method has been developed to synthesize nano-scale capsules loaded with
high payloads of high relaxivity MRI contrast agent. The cross-linked encapsulating
shell of these capsules affords the promise of high stability and robustness, rendering the
capsules more appropriate for in vivo applications. To test this resilience of CACs to
different pH regimes and metal ion concentration was examined. Suspensions of CACs
were incubated at pH 3, 5, 7, 9 and 11 and in the presence of 5 mM CaCl2 and 5 mM
MgCl2 and 200 mM NaCl.

These values exceed the range of pH and metal ion

concentration found in physiological fluids. In addition to the long term stability of the
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CACs, the effect of metal ions on relaxivity was also of interest, since both Ca2+ and
Mg2+ are known to bind to GdDOTP5-, quenching relaxivity. The CACs were analyzed
in terms of their size (DLS), relaxivity (T1 relaxometry) and morphology (SEM).

3.1.13: The effect of pH on CAC Stability
The structure of cross linked assembled capsules is held together by the peptidic bonds of
the encapsulating shell. It is reasonable to expect that these bonds and the electrostatic
interactions in the CAC interior may be disrupted by changes in pH. To examine any
response to changes in pH on the structure of CACs, they were dispersed in solutions of
pH 3, 5, 7, 9, and 11 and incubated for 4 weeks. The solutions were prepared by
combining deionized water, HCl (12 M) or NaOH (5M) to achieve the desired pH. 1 mL
of a CAC suspension was placed in a dialysis membrane which was placed in a solution
at the pH to be studied. Capsules were removed from the dialysis membrane after each
week for characterization.

Before making relaxation measurements capsules were

washed twice with DI water to make sure that no influence on the relaxivity values is a
contribution from the salts. No apparent change in the size of the capsules was observed
over four weeks at any pH studied (Figure 3.21). Furthermore, SEM images show no
notable change in capsules morphology over the same period.
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Figure3.20: SEM images of CACs exposed to pH 3-11 from day 0 to day 28 for R = 0.3
The per-Gd3+ relaxivity for CACs incubated between pH 3 and pH 9 remains essentially
constant over the course of 4 weeks. This suggests that in addition to the capsules
retaining their shape and size, there is no appreciable release of the chelate or change in
the protons (or water) transfer rate in the pH range 3-9.

In contrast, at pH 11, a

continuous superlinear drop in relaxivity was observed for pH 11 over the course of the
experiment. Given the capsules do not seem to change size or shape significantly at this
pH the most likely explanation for this drop in relaxivity is base catalysed hydrolysis of
the Gd3+ ion from DOTP. This would produce the insoluble Gd (OH)3(H2O)6 which
would account for the drop in relaxivity.
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Figure 3.21: A comparison of CAC% change in Gd3+ relaxivity and average size of
capsules over 28 days at different pH values pH 3(red diamonds),pH 5 (orange
diamonds), pH 7 (green triangles), pH 9(blue circles), pH 11(purple circles) and salts
NaCl (blue circles), CaCl2 (green squares) and MgCl2 (red squares
3.1.14: The effect of metal ions on CAC stability.
In biological fluids several metal ions are abundant that may modulate the strength of
electrostatic interactions. To study whether some of the most abundant metal ions affect
the function of CACs as MRI contrast agents, CACs were suspended in dialysis
membranes in solutions of 5 mM CaCl2, 5 mM MgCl2 and 200 mM NaCl.

Ca2+
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accomplishes most of its biological process in the presence of Mg2+ so it was important to
study both these ions on their effect on the CACs. The experimental design was the same
as that used for the pH. CACs were suspended in dialysis membranes in solutions of the
metal ion of interest. The capsules were sampled each week during the 4 weeks of
incubation in solutions of metal ions. Capsule size was measured by DLS and the
relaxation rate constants were measured at day 0 and each 7 days thereafter. SEM images
were taken (Figure 3.22) at the beginning and end of the incubation period to assess
changes to the morphology of the capsules. Size of the capsules was not affected by
incubation in the presence of the endogenous metal ions Ca2+, Mg2+, and Na+.
Furthermore, no change was observed in the relaxivity value of these capsules (Figure
3.19). This is of particular relevance in the case of Mg2+ and Ca2+, both of which are
known to bind to GdDOTP5- and quenching relaxivity. This suggests that the polymer
hydrogen bonds to the phosphonate groups in such a way as to block the metal ion
binding, which quenches relaxivity. These salts also seem to have no effect on the
electrostatics of the capsules, no disassembling of these capsules was observed based on
the size analysis and the morphology studies using the SEM (Figure 3.22).
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Figure 3.22: SEM images of CACs suspended in 5 mM CaCl2, MgCl2 and NaCl for day
0 and day 28respectively
MRI offers high spatial resolution, but in order to be used for molecular imaging
applications it is necessary to deliver a high payload of Gd3+ to a specific pathology.
CACs represent a solution to delivering high payloads of the Gd3+ chelates to the target
site. Moderately sized (≤ 30kDa) targeted contrast agents are often preferred because
their small size enables them to diffuse freely to small areas and their simple clearance,
but this type of targeted imaging tend to suffer low sensitivity with small Gd3+ based
contrast agents.119, 120 Contrast agents that possess high relaxivity and the capability to
deposit high payloads of contrast agents are more desirable from a detectability point of
view. This may limit the applications for which they can be used by their distribution
characteristics but their use will not have the same detection limitations.

The

development of such an agent may be envisioned through the attachment of a targeting
moiety on the surface of the CAC. A lot of work has been performed by conjugating
targets112 and many other techniques which allows attachment of targeting moieties on
the surface or link them to contrast agents. Selective coupling of primary amino groups
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to isothiocyanate is one of the methodologies which have been used under mild
conditions. To investigate whether it is possible to undertake such a coupling reaction on
the surface of Gd3+ chelates containing CACs, a sample of the prepared R = 0.5 CACs
where treated with FITC, an isothiocyanate was dissolved in DSMO at 1 mg/mL and was
prepared fresh for each labelling and for every 1 mL of CACs, 50 µL of FITC solution
was added. CACs were suspended in 0.1 M sodium carbonate buffer at pH 9 and the
buffer was prepared fresh, to make sure that pH of the buffer does not change upon
storage. Thorough washing was performed on the CACs to remove unreacted dye and
CACs were imaged using a confocal microscope (Figure 3.23).

The intense green

emission from the capsules indicates that FITC was able to access and react with primary
amino groups on, or close to, the surface of capsules. This shows that it should be
possible to conjugate a targeting moiety on the surface of the CAC producing targeted
high payload contrast agents with enhanced relaxivity.

Increasing the payload by

synthesizing the CAC has shown to give high per-Gd3+ relaxivity values and
incorporating many high relaxivity contrast agents in each capsule affords exceptionally
high per-capsule relaxivities. This means that each capsule will have very significant
effects on water proton T1s reducing the detection limit of any agent targeted to a specific
pathology of interest in molecular imaging applications. We have also investigated the
availability of primary amino functions on the surface of CACs with FITC to quantify the
availability of these functional groups.
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Figure 3.23: Bright field optical field microscopy image of R = 0.5 CACs prepared with
GdDOTP5- and treated with FITC after. 63xmagnification; excitation laser line 488 nm;
excitation wavelength 500 nm; emission wavelength 555 nm; scan format 512 x 512
pixels
3.1.16 Conclusions
A new method for robust encapsulating nano-assembled capsules has been developed.
This method is tolerant of charge ratios (R) from 0.3 to 1.0, beyond a charge ratio of 1
capsule were difficult to synthesize.

There was a stronger but similar relationship

between the value of R and the size of capsules than for NACs. The smallest capsules
where obtained by using this alternative method of coating combined with a low R value.
These very small capsules (127 nm) afforded the highest relaxivity values to date, almost
twice as high as those of capsules coated with SiO2nanoparticles. The interaction of
GdDOTP5- with the cationic polymer limits the freedom of motion of the chelate and
brings exchangeable protons into close contact with the chelate through the “second–
sphere”.121,

122

This is the origin of the enhanced relaxivity. The alternative coating

method allows movement of water molecules across the coating and does not have a
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limiting effect on relaxivity. The surface of CACs possess free amines which have been
shown to be reactive to external labelling approaches, such as FITC a fluorescent agent as
demonstrated by confocal microscopy. The availability of reactive free amines on the
surface of CACs is an added advantage of these capsules because they provide a method
for attaching targeting moieties to the surface of these capsules. The stability of CACs
were also explored in this chapter for different metal ions (200 mM Na+, 5mM Ca2+ and
5mM Mg2+) and pH values (3–11). CACs were found to be robust in the presence of all
of the metal ions studied for the duration of the four week experiment. The relaxivity
remained constant for four weeks and no detectable change in the size or morphology of
the CACs was observed. The effect of incubating CACs in solutions from pH 3–9 was
found to be similar. However, at pH 11 incubation has a substantial effect on relaxivity
(presumably the result of metal hydrolysis) but the size and morphology of the CACs
seem to be unaffected. We can conclude that CACs are stable against many of the likely
sources of interference from the constituents of extracellular fluids and represent good
candidates for the development of high relaxivity, high payload molecular imaging
agents.
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Chapter 4. Synthesis of a reverse NAC as a paraCEST agent
4.1. Introduction
MRI is a clinical diagnostic method widely used in the medical field for anatomical
imaging ,owing to its spatial and anatomical resolution. Gd3+ complexes are widely used
as MRI contrast agents in clinical diagnostic medicine. These MRI agents lack tissue
specificity and they do not respond to their chemical environment, therefore work has
been performed where MRI contrast can be altered based on chemical exchange
saturation transfer (CEST). Paramagnetic metal complexes that can shift the frequency
of an exchanging site in a chelate far from the bulk water signal may be able to function
as a CEST agent. Lanthanides ions such as Eu3+, Ho3+, Dy3+, Yb3+ and Tm3+ have near
ideal properties as paramagnetic CEST agents. Complexes formed from these ions and
neutral ligands such as tetramides derivates of DOTA has the slower water exchange
rates required of CEST agents. Unlike Gd3+, these lanthanide metals have low relaxivity
but when operating as paraCEST they maintain an ability to effect changes on image
contrast123. One of the major advantages of using paraCEST agents is the ability to turn
them on and off by changing the pulse sequence parameters. It is only when a presaturation pulse is situated at the resonance frequency of the bound water molecule or
exchangeable amides protons will the image exhibit CEST contrast. A pre-saturation
pulse at any other frequency will not affect the image. And because these paraCEST
agents have very low relaxivities they do not substantially alter the image through
changes in T1 or T2. This feature is unlike Gd3+ chelates which are always on and affect
the image until the Gd3+ chelate has been cleared from the body. This limits the timing of
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the acquisition of pre- and post-contrast images. In molecular imaging applications it is
envisioned that the post-contrast image will be acquired after administration of the
contrast agent and after the agent has cleared from healthy tissue. This will clearly be a
long time after the acquisition of the pre-contrast image, creating problems for the coregistration of the two images. A contrast agent, such as paraCEST agent, that can be
switched on and off will offer a significant advantage because the pre- and post-contrast
images can be collected one after the other faciltating better co-registration of the images.
One of the major limitations of CEST is the inherent sensitivity of paraCEST agents.
However, entrapping paraCEST agents in nano-scale capsules could deliver a large
payload of a paraCEST agent and improve the limit of detection for these agents. This
opened new avenues for the discovery of new classes of responsive agents like MR gene
reporters to small molecules that respond to biological events.

Since the first

demonstration of paraCEST contrast agents by Zhang and his co workers in 200182, they
have been explored for a number of biomedical applications for different targets pH72, 124,
temperature125,

126

, enzymes127,

128

, metabolites129-131 and metal ions.132,

133

Use of

paraCEST contrast agents have shown promise in in vivo system application. The biggest
challenge of paraCEST contrast agents method in in vivo is loss of sensitivity and poor
temporal resolution for detection, due to magnetization transfer from endogenous
macromolecules following application of radio frequency pulse that saturates bulk water
spins lowering the contrast efficiency of ParaCEST agents.

Currently available

ParaCEST agents are inherently insensitive as imaging agents, therefore they require
agents in the millimolar range. A number of approaches for increasing the proton or

CHAPTER 4. Preparation of Reverse NACs

74

water exchange rates and the number of exchangeable groups per agent, and the latter
approach seems to be more promising87, 134, 135, therefore incooperation of contrast agents
into nano assembled capsules is another way to increase contrast agent localization, it is a
more effective way to increase contrast agent molecules to a region with highly loaded
capsules with the contrast agent. There are a number of nanoparticle strategies that have
been investigated to enhance the sensitivity of CEST contrast agents. Entrapment of
CEST contrast agents involves binding the CEST agent to the nanoparticle structure
physically or trapping the contrast agent and chemically attaching a CEST agent both
diaCEST and ParaCEST agents have been demonstrated to be trapped using polymers136138

, liposomes111, 139 and dendrimers87, 140 and where able to generate a CEST effect. In

this chapter we investigated one system where we synthesized a reverse NAC by
incorperating a traditional ParaCEST DyDOTAM3+.

Scheme 6: The structure of the chelate used in the synthesis of the reverse NACs
4.2: Experimental
4.2.1: General remarks
A solution of polyacrylic acid (100,00 MW acrylic units per molecule, 35 wt % in water)
and poly allyamine hydrochloride (56, 000 MW ~ 596 allylamine units per molecule)
were purchase at sigma Aldrich. Ethylene diamine (EDA) was purchased from J.T
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Baker. A suspension of SiO2 NP (Snowtex-O type, 20.3 wt % SiO2 NP, and pH 3.5 was
purchased from Nissan chemicals and the pH adjusted to 5.5 using 150 mM NaOH prior
to use. Deionized water (18.2 MΩ, Barnstead Nanopure Diamond System) was used in
all reactions
4.2.2: Reverse NAC synthesis
An aqueous solution of PAA (215 𝜇L, 5 mg/mL) was mixed with an aqueous
DyDOTAM3+ solution (535 𝜇L, 40 mM) in a 1.5 mL eppendorf centrifuge tube and
vortex mixed for 10 seconds at low speed. A charge ratio R = 0.5 (equation 2.1) was
studied in this work, the EDA concentration was 0.11 M. A turbid mixture immediately
resulted, indicating the formation of PAA-DyDOTAM aggregates the reaction mixture
was vortexed at a very low speed for 5 seconds and aged for 10 seconds, and an aqueous
solution of PAH (20 µL, 89 µM) was added to the turbid solution of PAA-DyDOTAM
aggregates and vortexed at a low speed for 10 seconds and aged for 15 seconds. EDA
was added (215 µ𝐿) to the turbid solution and there was an increase in turbidity. This
suspension was aged for 10 seconds, before an aqueous SiO2NPs suspension (535 𝜇L;
concentration of 2.0 wt %) was added. The resultant mixture was stirred vigorously at a
medium speed for 10 seconds and aged for 2 hrs. Unreacted starting materials were
removed by filter centrifugation using 10 kDa MWCO filter centrifuge tube.

4.3: Results and Discussion
It has been successfully shown in our earlier work that NACs are a versatile platform for
the development of high payload contrast agents. However, assembly had previously
been limited to a cationic polymer, multivalent anionic contrast agents, and negatively
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We wondered whether NAC synthesis could be made in a reverse

assembly methodology, comprising an anionic polymer, multivalent cationic contrast
agents, and negatively charged NPs. The motivation for this reversal is the possibility to
incorporate a positively charged paraCEST contrast agent into the capsule. For this
reason Gd3+ is replaced by Dy3+, because Dy3+ has near ideal properties as a
paramagnetic CEST agent when chelated with a neutral ligand such as DOTAM. Dy3+
significantly shifts the amide protons of the ligand which are in slow exchange with
water; however, once inside a capsule it is not clear that this chelate will continue to
function as a CEST agent since the rate at which protons exchange may change due to
hydrogen bonding interactions. However, if exchange remains in the slow regime then
the concept of reverse assembly may facilitate a method by which high loadings of
positively charged chelates can be achieved. In addition to high payloads of CEST agent,
one other approach to increasing the sensitivity of CEST is to increase the number of
exchangeable protons per agent. For this reason DyDOTAM3+ was chosen as the CEST
agent. In addition to 2 exchanging water protons shifted to -760 ppm, this chelate has 8
amide protons that can exchange slowly with water shifted to +90 ppm. To achieve the
reverse NAC synthesis DyDOTAM3+ was mixed with the anionic polymer polyacrylic
acid (PAA) in an aqueous solution and PAA at pH of 7. Upon mixing the solution
rapidly went turbid, a strong indication of aggregate formation.

Encapsulating this

aggregate proved more challenging because the aggregate surface is predominantly
negatively charged as are SiO2NPs. For this reason initial attempts at encapsulation were
performed using EDC and polyamines in an attempt to cross-link the capsule shell (c.f.
Chapter 3).

However, this approach, while theoretically viable, currently remains
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unsuccessful. An alternative strategy was therefore pursued in which the aggregate
surface was charge modified prior to addition of SiO2NPs. A solution of the cationic
PAH was added to the aggregates after 10 seconds of aging followed by ethylene diamine
and aggregates aged for 10 seconds before SiO2NPs were added to encapsulate the, now
positively charged, aggregate. Spherical capsules were formed which appear similar by
SEM to those formed using PAH and anionic chelates (Figure 4.24). The size of capsules
was measured using dynamic light scattering and was found to be 650 ± 250 nm. These
reverse NACs are much larger than the NACs prepared using PAH and anionic chelates
at the same charge ratio NACs. For example, NACs prepared with the trianionic chelate
GdTTHA3- had an average size of 180 nm, less than a third of the size of the650 nm
determined for the reverse capsules. It is speculated that this difference arises from
differences in the strength of the interaction of the anion and cation in the aggregate, the
additional polymer layer than needed to be added and a difference in the interaction of
the SiO2NPs with this additional polymer layer, versus the PAH of the aggregates in the
NACs.

Figure 4.24: SEM images for reverse NACs for DyDOTAM/PAA for R = 0.5
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Figure 4.25: CEST spectra of 40 mM DyDOTAM chelate solution (red circles) and 40
mM DyDOTAM NACs (blue circles)
The CEST spectrum of DyDOTAM3+ is shown in Figure 4.25. A CEST peak arising
from DyDOTAM3+ is clearly visible at +90 ppm from the bulk water, which is known to
arise from the 8 amide protons.

However, the CEST spectrum of DyDOTAM3+

containing reverse NACs shows no CEST peak at all in this part of the spectrum. This
disappointing result may have several causes: T1/T2, concetration, acceleration of
exchange beyond the slow exchange regime, inihibition of exchange by aggregate
formation. In these experiments CEST from the bound water molecule at -760 ppm was
not investigated. However, going forward this is an important factor to investigate since
one may envision amide protons interacting directly with the PAA of the aggregate. In
contrast, the bound water may have no direct interaction at all and its CEST properties
may be largely unaffected by encapsulation it was difficult to observe a CEST signal for
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79
We speculated that

encapsulation of this chelate reduces rotational correlation time and lengthens R1 and R2
this has a consequence that direct saturation of the water protons surpasses the CEST
effect, hence we did not observe a CEST signal from these reverse NACs.
4.5: Conclusions
A novel approach was developed to synthesize reverse NACs containing paraCEST
agents and CEST data was acquired to assess the effect of encapsulation. No observable
CEST was observed from the amide protons of DyDOTAM3+ upon encapsulation of the
chelates. We speculate that as we encapsulate the chelate there is an increase in exchange
rate and it increased a maximum and ∆𝜔 begins to broaden and decrease and the
exchange peak shifts towards the bulk water frequency (0 ppm). This causes the CEST
signal to disappear completely when the exchange is too fast hence no observable
difference between the bound and bulk water protons can be observed. There is still a lot
to be investigated on the concept of reverse paraCEST agents.
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